<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mamm Genome</journal-id>
<journal-id journal-id-type="iso-abbrev">Mamm. Genome</journal-id>
<journal-title-group>
<journal-title>Mammalian Genome</journal-title>
</journal-title-group>
<issn pub-type="ppub">0938-8990</issn>
<issn pub-type="epub">1432-1777</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30820643</article-id>
<article-id pub-id-type="pmc">6606665</article-id>
<article-id pub-id-type="publisher-id">9793</article-id>
<article-id pub-id-type="doi">10.1007/s00335-019-09793-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Treating Rett syndrome: from mouse models to human therapies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vashi</surname>
<given-names>Neeti</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Justice</surname>
<given-names>Monica J.</given-names>
</name>
<address>
<phone>+416-813-7654</phone>
<email>monica.justice@sickkids.ca</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0473 9646</institution-id><institution-id institution-id-type="GRID">grid.42327.30</institution-id><institution>Genetics and Genome Biology Program, </institution><institution>The Hospital for Sick Children, The Peter Gilgan Centre for Research and Learning, </institution></institution-wrap>Toronto, ON M5G 0A4 Canada </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Department of Molecular Genetics, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON M5S 1A1 Canada </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>28</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>30</volume>
<issue>5</issue>
<fpage>90</fpage>
<lpage>110</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Rare diseases are very difficult to study mechanistically and to develop therapies for because of the scarcity of patients. Here, the rare neuro-metabolic disorder Rett syndrome (RTT) is discussed as a prototype for precision medicine, demonstrating how mouse models have led to an understanding of the development of symptoms. RTT is caused by mutations in the X-linked gene methyl-CpG-binding protein 2 (<italic>MECP2</italic>). <italic>Mecp2-</italic>mutant mice are being used in preclinical studies that target the <italic>MECP2</italic> gene directly, or its downstream pathways. Importantly, this work may improve the health of RTT patients. Clinical presentation may vary widely among individuals based on their mutation, but also because of the degree of X chromosome inactivation and the presence of modifier genes. Because it is a complex disorder involving many organ systems, it is likely that recovery of RTT patients will involve a combination of treatments. Precision medicine is warranted to provide the best efficacy to individually treat RTT patients.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Understanding and developing therapies for rare disorders</title>
<p id="Par2">Rett syndrome (RTT) is a rare disorder that occurs in 1 in 10,000 females (Rett <xref ref-type="bibr" rid="CR167">1966</xref>; Haas <xref ref-type="bibr" rid="CR79">1988</xref>). It is characterized by seemingly normal neurological and physical development during the early postnatal period, followed by symptom manifestation between 6 and 18 months of age (Hagberg <xref ref-type="bibr" rid="CR82">2002</xref>). Symptoms progress over several stages (Table <xref ref-type="table" rid="Tab1">1</xref>): stagnation, rapid regression, plateau, and late motor deterioration. The stagnation stage is characterized by subtle developmental delays in motor and language skills, and possible decreased alertness. This stage is often overlooked and leads to a delayed diagnosis, as parents and doctors may not notice these subtle changes. During the rapid regression stage, the child loses purposeful hand skills and spoken language, experiences motor impairments, and develops breathing abnormalities. Children may develop autistic-like features such as loss of interest in social interaction, and seizures may occur. This is followed by the plateau stage, during which motor problems and seizures become more common, but communication skills may improve. Lastly, children enter the late motor deterioration stage during which severe physical disability is common, and many patients become wheelchair dependent.</p>
<p id="Par3">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Rett syndrome progresses over several stages</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Stage</th><th align="left">Age</th><th align="left">Symptoms</th></tr></thead><tbody><tr><td align="left">1. Stagnation</td><td align="left">6–18 months</td><td align="left"><p>• Developmental delays (postural control, motor, language)</p><p>• Reduced eye contact</p><p>• Hand-wringing may occur</p><p>• Microcephaly may occur</p></td></tr><tr><td align="left">2. Rapid regression</td><td align="left">1–4 years</td><td align="left"><p>• Loss of purposeful hand skills</p><p>• Stereotypical hand movements (wringing, washing, tapping)</p><p>• Loss of spoken language</p><p>• Walking may be unsteady</p><p>• Breathing irregularities may occur</p><p>• Autistic-like features</p><p>• Microcephaly progression</p><p>• Seizures may occur</p></td></tr><tr><td align="left">3. Plateau/pseudo-stationary</td><td align="left">2–potentially life</td><td align="left"><p>• Hand apraxia/dyspraxia</p><p>• Motor coordination difficulties and/or loss of motor skills</p><p>• Improvement of communication skills may occur</p><p>• Seizures are common</p></td></tr><tr><td align="left">4. Late motor deterioration</td><td align="left">10–life</td><td align="left"><p>• Severe physical disability</p><p>• Muscle weakness, rigidity, or spasticity</p><p>• Wheelchair dependency may occur</p></td></tr></tbody></table></table-wrap>
</p>
<p id="Par4">Independent of disease stage, subsets of patients also experience gastrointestinal problems (Motil et al. <xref ref-type="bibr" rid="CR140">2012</xref>), abnormal cardiorespiratory coupling (Kumar et al. <xref ref-type="bibr" rid="CR109">2017</xref>), decreased bone density (Shapiro et al. <xref ref-type="bibr" rid="CR181">2010</xref>), early-onset osteoporosis (Haas et al. <xref ref-type="bibr" rid="CR81">1997</xref>), bruxism (Alpoz et al. <xref ref-type="bibr" rid="CR4">1999</xref>), dyslipidaemia (Justice et al. <xref ref-type="bibr" rid="CR95">2013</xref>; Segatto et al. <xref ref-type="bibr" rid="CR178">2014</xref>), inflammation of the gallbladder (Anderson et al. <xref ref-type="bibr" rid="CR7">2014</xref>), scoliosis (Anderson et al. <xref ref-type="bibr" rid="CR7">2014</xref>), urological dysfunction (Ward et al. <xref ref-type="bibr" rid="CR198">2016</xref>), and sleep disturbances (Young et al. <xref ref-type="bibr" rid="CR204">2007</xref>). Additionally, RTT patients have an increased incidence of unexpected death, and often die due to respiratory infection, cardiac instability, and respiratory failure (Laurvick et al. <xref ref-type="bibr" rid="CR115">2006</xref>; Anderson et al. <xref ref-type="bibr" rid="CR7">2014</xref>). Current treatment options are limited to symptom control.</p>
</sec>
<sec id="Sec2">
<title>Rett syndrome is caused by mutations in methyl-CpG-binding protein 2 (<italic>MECP2</italic>)</title>
<p id="Par5">Although a genetic basis for RTT was hypothesized as early as 1983 based on the preferential involvement of females (Hagberg et al. <xref ref-type="bibr" rid="CR84">1983</xref>), it was not until 1999 that a causative gene for the disorder was identified. Using a systematic gene screening approach, Amir et al. identified mutations in the gene methyl-CpG-binding protein 2 (<italic>MECP2</italic>) as the cause of some cases of RTT (Amir et al. <xref ref-type="bibr" rid="CR6">1999</xref>). It is now known that <italic>de novo</italic> mutations in <italic>MECP2</italic> account for 95% of typical RTT cases (Bienvenu et al. <xref ref-type="bibr" rid="CR17">2000</xref>). Although nearly 600 RTT-causing mutations have been identified in <italic>MECP2</italic>, only eight missense and nonsense mutations account for approximately 70% of mutations in RTT (R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C) (Neul et al. <xref ref-type="bibr" rid="CR149">2008</xref>). Large deletions in <italic>MECP2</italic> account for another 15% of RTT-causing mutations. Interestingly, additional mutations in <italic>MECP2</italic> have been associated with autism (Xi et al. <xref ref-type="bibr" rid="CR202">2011</xref>), intellectual disability (Bianciardi et al. <xref ref-type="bibr" rid="CR16">2016</xref>), and lupus erythematosus (Liu et al. <xref ref-type="bibr" rid="CR124">2013</xref>).</p>
<p id="Par6"><italic>MECP2</italic> encodes a nuclear protein (<italic>MECP2</italic>), which is especially abundant within neurons but is expressed at varying levels in every human tissue (Lewis et al. <xref ref-type="bibr" rid="CR119">1992</xref>; Tate et al. <xref ref-type="bibr" rid="CR189">1996</xref>; Shahbazian et al. <xref ref-type="bibr" rid="CR180">2002b</xref>). It is comprised of four domains and is host to several posttranslational modifications (Reviewed in Kyle et al. <xref ref-type="bibr" rid="CR113">2018</xref>). <italic>MECP2</italic> functions as a global transcriptional regulator by binding specifically to methylated DNA, recruiting protein partners and regulatory complexes to modify transcriptional activity (Nan et al. <xref ref-type="bibr" rid="CR147">1997</xref>; Chandler et al. <xref ref-type="bibr" rid="CR30">1999</xref>). Although <italic>MECP2</italic> is thought to primarily repress gene transcription, its role in transcriptional activation (Chahrour et al. <xref ref-type="bibr" rid="CR29">2008</xref>), chromatin remodeling, and mRNA splicing has also been described (reviewed in Lyst and Bird <xref ref-type="bibr" rid="CR127">2015</xref>). <italic>MECP2</italic> expression correlates with the postnatal maturation of the central nervous system (CNS) and neuronal differentiation, suggesting a role in CNS function and maintenance (Kishi and Macklis <xref ref-type="bibr" rid="CR100">2004</xref>). Within the brain, <italic>MECP2</italic> is seven times higher in neurons than in glia; however, <italic>MECP2</italic> has important roles in glia as well (Ballas et al. <xref ref-type="bibr" rid="CR11">2009</xref>; Skene et al. <xref ref-type="bibr" rid="CR184">2010</xref>; Lioy et al. <xref ref-type="bibr" rid="CR123">2011</xref>).</p>
<p id="Par7">Clinical studies have highlighted the degree of phenotypic variation in Rett syndrome patients (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a). Genotype–phenotype correlation studies demonstrate that early truncating mutations in <italic>MECP2</italic> (R168X, R255X, and R270X) and large INDELs cause the most severe phenotype, whereas most missense mutations (R133C and R306C) and late truncating mutations (R294X) are the mildest (Neul et al. <xref ref-type="bibr" rid="CR149">2008</xref>; Cuddapah et al. <xref ref-type="bibr" rid="CR40">2014</xref>). Thus, <italic>MECP2</italic> mutation status is a predictor of disease severity. Despite this, phenotypic variation is also reported in familial cases of RTT where affected sisters present with the same mutation (Zhang et al. <xref ref-type="bibr" rid="CR206">2017</xref>); these differences may be due to differences in X chromosome inactivation (XCI). Because <italic>MECP2</italic> is inherited on the X chromosome, female heterozygous RTT patients are mosaic carriers of normal and mutated <italic>MECP2</italic>. XCI is a random process by which one X chromosome is silenced in each cell. XCI can be skewed where the X chromosome carrying the mutated <italic>MECP2</italic> is more or less expressed throughout the brain and body, influencing the clinical presentation of RTT (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b) (Ishii et al. <xref ref-type="bibr" rid="CR89">2001</xref>; Knudsen et al. <xref ref-type="bibr" rid="CR101">2006</xref>). Tests for skewed XCI are possible in the clinic. In cases where XCI is not skewed toward one allele, phenotypic variation may be due to the presence of modifier mutations. Modifiers are genes whose function has phenotypic outcomes on the effect of another gene. Mutations in modifier genes may alleviate or enhance clinical symptoms in patients as well (Fig. <xref ref-type="fig" rid="Fig1">1</xref>c).</p>
<p id="Par8">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Symptom severity in RTT is influenced by mutation status, XCI pattern, and modifier genes. <bold>a</bold> Of the 8 most common RTT-causing <italic>MECP2</italic> mutations, R133C and R306C cause the least severe clinical presentation, whereas the missense mutations R106W and T158M, and nonsense mutations R168X, R255X, R270X, and R294X cause the most severe phenotype. Large deletions in the <italic>MECP2</italic> gene also cause a severe phenotype, whereas smaller C-terminal truncations are less severe. <bold>b</bold> Differences in XCI skewing patterns can influence clinical presentation, where patients with fewer cells expressing the mutant <italic>MECP2</italic> gene will have less severe symptoms. <bold>c</bold> Individuals who have modifier mutations in genes that suppress the RTT phenotype have a more favorable clinical presentation than individuals with mutations in genes that enhance detrimental symptoms</p></caption><graphic id="d29e614" xlink:href="335_2019_9793_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec3">
<title>Mouse models recapitulate key symptoms of RTT</title>
<p id="Par9"><italic>Mecp2</italic> is found in all vertebrates, but not in non-vertebrate genetic model organisms, including the fruit fly or the worm (Hendrich and Tweedie <xref ref-type="bibr" rid="CR87">2003</xref>). Therefore, developing mouse models of the disorder was needed for a mechanistic understanding of the onset and severity of clinical signs. Shortly after the identification of <italic>MECP2</italic> as the causative gene in RTT, two <italic>Mecp2-</italic>null mouse models were generated, which are now the primary models used to study the disease (Table <xref ref-type="table" rid="Tab2">2</xref>). The <italic>Mecp2</italic><sup><italic>tm1.1Bird</italic></sup> mouse line completely lacks <italic>MECP2</italic> protein product (Guy et al. <xref ref-type="bibr" rid="CR76">2001</xref>), whereas the <italic>Mecp2</italic><sup><italic>tm1.1Jae</italic></sup> line expresses small <italic>MECP2</italic> protein fragments (Chen et al. <xref ref-type="bibr" rid="CR33">2001</xref>). However, both null models display a similar phenotype that recapitulates symptoms of RTT and both have been used extensively to study the mechanistic basis for disease.</p>
<p id="Par10">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Many mouse models have been created to study Rett syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Allele type</th><th align="left" rowspan="2">Allele</th><th align="left" rowspan="2">Description</th><th align="left" colspan="7">Male phenotype</th><th align="left" rowspan="2">References</th></tr><tr><th align="left">RB</th><th align="left">BW</th><th align="left">BR</th><th align="left">AX</th><th align="left">M</th><th align="left">PD</th><th align="left">Age of death (weeks)</th></tr></thead><tbody><tr><td align="left" colspan="11">
<bold>Null</bold>
</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Null</td><td align="left">Exon 3–4 deletion</td><td align="left">X</td><td align="left">X^</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">6–12</td><td align="left">Guy et al. (<xref ref-type="bibr" rid="CR76">2001</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">Null; some protein product retained</td><td align="left">Exon 3 deletion</td><td align="left">X</td><td align="left">X*</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">10</td><td align="left">Chen et al. (<xref ref-type="bibr" rid="CR33">2001</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Pplt</italic></sup>
</td><td align="left">Null</td><td align="left">MBD deletion</td><td align="left">X</td><td align="left">X</td><td align="left">NT</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">8</td><td align="left">Pelka et al. (<xref ref-type="bibr" rid="CR159">2006</xref>)</td></tr><tr><td align="left" colspan="11">
<bold>Human point mutations</bold>
</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm4.1Joez</italic></sup>
</td><td align="left">R106W</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td><td align="left">X</td><td align="left">10</td><td align="left">Unpublished; MGI submission</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Nlnd</italic></sup>
</td><td align="left">Y120D</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">X</td><td align="left">NT</td><td align="left">–</td><td align="left">X</td><td align="left">X</td><td align="left">14–17</td><td align="left">Gandaglia et al. (<xref ref-type="bibr" rid="CR64">2018</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm6.1Bird</italic></sup>
</td><td align="left">R133C</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">X</td><td align="left">NT</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">42</td><td align="left">Brown et al. (<xref ref-type="bibr" rid="CR22">2016</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Joez</italic></sup>
</td><td align="left">T158A</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">–</td><td align="left">NT</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">16</td><td align="left">Goffin et al. (<xref ref-type="bibr" rid="CR67">2011</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm4.1Bird</italic></sup>
</td><td align="left">T158M</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">X</td><td align="left">NT</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">13</td><td align="left">Lyst et al. (<xref ref-type="bibr" rid="CR128">2013</xref>), Brown et al. (<xref ref-type="bibr" rid="CR22">2016</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm3.1Joez</italic></sup>
</td><td align="left">T158M</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td><td align="left">X</td><td align="left">14</td><td align="left">Unpublished; MGI submission</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jtc</italic></sup>
</td><td align="left">R168X</td><td align="left">Stop mutation; truncation</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">12–14</td><td align="left">Lawson-Yuen et al. (<xref ref-type="bibr" rid="CR116">2007</xref>), Schaevitz et al. (<xref ref-type="bibr" rid="CR175">2013</xref>), Wegener et al. (<xref ref-type="bibr" rid="CR199">2014</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Irsf</italic></sup>
</td><td align="left">R255X</td><td align="left">Stop mutation; truncation</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">8–10</td><td align="left">Pitcher et al. <xref ref-type="bibr" rid="CR161">(2015</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm5.1Bird</italic></sup>
</td><td align="left">R306C</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">X</td><td align="left">NT</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">30</td><td align="left">Lyst et al. (<xref ref-type="bibr" rid="CR128">2013</xref>), Brown et al. (<xref ref-type="bibr" rid="CR22">2016</xref>)</td></tr><tr><td align="left" colspan="11">
<bold>Other mutations</bold>
</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm2.1Jae</italic></sup>
</td><td align="left">S80A</td><td align="left">Missense mutation</td><td align="left">NT</td><td align="left">X*</td><td align="left">NT</td><td align="left">NT</td><td align="left">X</td><td align="left">NT</td><td align="left">NT</td><td align="left">Tao et al. (<xref ref-type="bibr" rid="CR187">2009</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Vnar</italic></sup>
</td><td align="left">A140V</td><td align="left">Missense mutation</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">Normal lifespan</td><td align="left">Jentarra et al. (<xref ref-type="bibr" rid="CR93">2010</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm3Meg</italic></sup>
</td><td align="left">T308A</td><td align="left">Missense mutation</td><td align="left">X</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td><td align="left">X</td><td align="left">NT</td><td align="left">&gt; 16</td><td align="left">Ebert et al. (<xref ref-type="bibr" rid="CR55">2013</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">R308X</td><td align="left">Stop mutation; truncation</td><td align="left">X</td><td align="left">–</td><td align="left">NT</td><td align="left">X*</td><td align="left">X</td><td align="left">X</td><td align="left">6–12</td><td align="left">Shahbazian et al. (<xref ref-type="bibr" rid="CR179">2002a</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Meg</italic></sup>
</td><td align="left">S421A</td><td align="left">Missense mutation</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">Normal lifespan</td><td align="left">Cohen et al. (<xref ref-type="bibr" rid="CR37">2011</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Mitoh</italic></sup>
</td><td align="left">Deletion</td><td align="left">Isoform 2 deletion</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">Normal lifespan</td><td align="left">Itoh et al. (<xref ref-type="bibr" rid="CR91">2012</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Dhy</italic></sup>
</td><td align="left">Deletion</td><td align="left">Isoform 1 deletion</td><td align="left">X</td><td align="left">–</td><td align="left">NT</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">7–31</td><td align="left">Yasui et al. (<xref ref-type="bibr" rid="CR203">2014</xref>)</td></tr><tr><td align="left" colspan="11">
<bold>Conditional alleles</bold>
</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Bird</italic></sup>
</td><td align="left">–</td><td align="left">Exons 3–4 floxed</td><td align="left">X*</td><td align="left">–</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">–</td><td align="left">Normal lifespan</td><td align="left">Guy et al. (<xref ref-type="bibr" rid="CR76">2001</xref>), Samaco et al. (<xref ref-type="bibr" rid="CR171">2008</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Jae</italic></sup>
</td><td align="left">–</td><td align="left">Exon 3 floxed</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">Normal lifespan</td><td align="left">Chen et al. (<xref ref-type="bibr" rid="CR33">2001</xref>)</td></tr><tr><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm2Bird</italic></sup>
</td><td align="left">–</td><td align="left">Floxed-stop upstream of exon 3</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">X</td><td align="left">8–10 weeks</td><td align="left">Guy et al. (<xref ref-type="bibr" rid="CR77">2007</xref>)</td></tr></tbody></table><table-wrap-foot><p>These mouse models include null alleles, point mutations designed to recapitulate mutations observed in human RTT patients, whole exon deletions, and conditional alleles used in combination with targeted Cre mice to achieve temporal deletion of <italic>Mecp2</italic>. In BW category, alleles marked with *which have an increased body weight, and alleles marked with ^show either increase or decrease depending on mouse background. In the AX category, alleles marked with *show increased anxiety</p><p><italic>RB</italic> reduced brain size, <italic>BW</italic> body weight reduction, <italic>BR</italic> breathing abnormalities, <italic>AX</italic> reduced anxiety, <italic>MA</italic> motor abnormalities, <italic>PD</italic> premature death In categories, <italic>X</italic> present, – not present, <italic>NT</italic> not tested</p></table-wrap-foot></table-wrap>
</p>
<p id="Par11">RTT predominantly affects females, so female <italic>Mecp2-</italic>mutant mice are the most clinically relevant model. However, female <italic>Mecp2-</italic>mutant mice display deviations in phenotype presentation due to XCI skewing making it difficult to discern which phenotypes arise through cell autonomous versus non-autonomous pathways. Therefore, the majority of RTT mouse studies take place in hemizygous <italic>Mecp2-</italic>mutant male mice due to their consistent phenotype and their complete lack of <italic>MECP2</italic> protein, which is advantageous for mechanistic research.</p>
<p id="Par12">Hemizygous male <italic>Mecp2</italic>-null mice are phenotypically normal until 4 weeks of age when they develop a RTT-like phenotype consisting of hind limb clasping, tremors, breathing irregularities, loss of muscle tone, and hypoactivity (Chen et al. <xref ref-type="bibr" rid="CR33">2001</xref>; Guy et al. <xref ref-type="bibr" rid="CR76">2001</xref>). These mice also display a reduced brain weight and body weight, experience a rapid phenotypic regression, and die between 6 and 12 weeks of age. Female mice heterogeneous for <italic>Mecp2</italic> deletions develop the same features at 4–6 months of age and typically live a normal lifespan.</p>
<p id="Par13"><italic>Mecp2-</italic>mutant mouse models recapitulate a broad spectrum of phenotypes seen in human RTT patients (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). The most profound symptoms in human patients and most <italic>Mecp2-</italic>mutant mice are motor abnormalities, including reduced mobility, impaired motor coordination, ataxic gait, and tremors (Hagberg and Witt-Engerström <xref ref-type="bibr" rid="CR83">1986</xref>). While human patients replace purposeful hand use with stereotypic movements, mouse models clasp their hindlimbs (Chen et al. <xref ref-type="bibr" rid="CR33">2001</xref>; Guy et al. <xref ref-type="bibr" rid="CR76">2001</xref>); this may resemble the hallmark human symptom, but it is not a phenotype specific to RTT mouse models (Lalonde and Strazielle <xref ref-type="bibr" rid="CR114">2011</xref>). Morphologically, both human patients and <italic>Mecp2</italic> mouse models exhibit a reduced brain volume and neuronal hypotrophy (Chahrour and Zoghbi <xref ref-type="bibr" rid="CR28">2007</xref>). Behaviorally, RTT patients experience a neurological regression and loss of speech, two traits which cannot be measured in mouse models. However, both may experience some learning deficits (Elefant and Wigram <xref ref-type="bibr" rid="CR57">2005</xref>; Moretti <xref ref-type="bibr" rid="CR138">2006</xref>). Interestingly, while human RTT patients typically exhibit increased anxiety and social avoidance (Mount et al. <xref ref-type="bibr" rid="CR141">2002</xref>), <italic>Mecp2</italic>-mutant mice are less anxious and more social, as assessed by phenotypic tests available for rodents (Samaco et al. <xref ref-type="bibr" rid="CR172">2012</xref>; Orefice et al. <xref ref-type="bibr" rid="CR154">2016</xref>; Wu et al. <xref ref-type="bibr" rid="CR201">2016</xref>). Metabolic disturbances in both human patients and mice include abnormalities in neurometabolites (Goffin and Zhou <xref ref-type="bibr" rid="CR68">2012</xref>), increased serum cholesterol and triglycerides (Buchovecky et al. <xref ref-type="bibr" rid="CR23">2013</xref>; Justice et al. <xref ref-type="bibr" rid="CR95">2013</xref>; Segatto et al. <xref ref-type="bibr" rid="CR178">2014</xref>; Kyle et al. <xref ref-type="bibr" rid="CR113">2018</xref>), abnormal mitochondrial structure (Shulyakova et al. <xref ref-type="bibr" rid="CR182">2017</xref>), and increased oxidative stress (De Felice et al. <xref ref-type="bibr" rid="CR42">2009</xref>; Janc et al. <xref ref-type="bibr" rid="CR92">2016</xref>). Finally, both experience breathing irregularities (Ramirez et al. <xref ref-type="bibr" rid="CR165">2013</xref>), cardiac abnormalities (prolonged QTc intervals) (McCauley et al. <xref ref-type="bibr" rid="CR132">2011</xref>; Hara et al. <xref ref-type="bibr" rid="CR86">2015</xref>), seizures, and a shortened lifespan (Guy et al. <xref ref-type="bibr" rid="CR76">2001</xref>; Anderson et al. <xref ref-type="bibr" rid="CR7">2014</xref>). Overall, <italic>Mecp2-</italic>mutant mice exhibit a broad range of phenotypes that recapitulate symptoms of human RTT patients, making them excellent models to study the disorder.</p>
<p id="Par14">
<fig id="Fig2"><label>Fig. 2</label><caption><p>RTT patients and <italic>Mecp2</italic>-mutant mouse models share many features</p></caption><graphic id="d29e1899" xlink:href="335_2019_9793_Fig2_HTML"></graphic></fig>
</p>
<p id="Par15">Despite their face validity, null mouse models do not always represent human cases molecularly since many RTT patients carry missense mutations that result in a less-efficient or unstable <italic>MECP2</italic> protein rather than a complete loss of it. To circumvent this caveat, several mouse lines with point mutations and deletions in <italic>MECP2</italic> have been engineered to recapitulate clinically relevant mutations observed in human patients (Table <xref ref-type="table" rid="Tab2">2</xref>). Of the eight most common missense mutations in RTT patients, six have an established mouse model which recapitulates symptoms of the disease. These mice have been instrumental in understanding the functional consequences of RTT-causing mutations and their correlation to symptom severity. For example, RTT patients carrying <italic>MECP2</italic> T158M mutations display severe RTT symptoms, while motor and speech preservation is observed in patients with a R133C mutation (Cuddapah et al. <xref ref-type="bibr" rid="CR40">2014</xref>). Consistently, male mice carrying these missense mutations have a lifespan of 13 weeks and 42 weeks, respectively. Functional studies in mice determined that while both the T158M and R133C mutations create <italic>MECP2</italic> proteins with reduced DNA-binding ability, the T158M mutation also leads to protein instability, likely resulting in the unique and more severe phenotype presentation (Brown et al. <xref ref-type="bibr" rid="CR22">2016</xref>).</p>
<p id="Par16">Further, mice with <italic>Mecp2</italic> mutations have been designed to study specific biological questions of functional relevance. For example, while <italic>MECP2</italic> is expressed as two isoforms, their expression levels vary among tissues, with <italic>MECP2</italic>_e1 being more abundant than e2 in the brain. Studies that deleted either <italic>MECP2</italic>_e1 or e2 throughout the body found that only deletion of <italic>MECP2</italic>_e1 led to RTT-like phenotypes and a shortened lifespan, while deletion of e2 was required for placental development (Itoh et al. <xref ref-type="bibr" rid="CR91">2012</xref>; Yasui et al. <xref ref-type="bibr" rid="CR203">2014</xref>). Additionally, <italic>MECP2</italic> protein is a host to numerous posttranslational modifications (PTMs), including phosphorylation at serine 80 (S80) and 421 (S421). Mutating either of these serine residues in mice prevented this site-dependent phosphorylation and determined that these PTMs are important for the association of <italic>MECP2</italic> to chromatin and its role in regulating neuronal gene expression (Tao et al. <xref ref-type="bibr" rid="CR187">2009</xref>; Cohen et al. <xref ref-type="bibr" rid="CR37">2011</xref>).</p>
<p id="Par17">Finally, conditional-ready alleles have been constructed by engineering <italic>lox</italic>P sites flanking a portion of the <italic>Mecp2</italic> gene (Floxed) (Chen et al. <xref ref-type="bibr" rid="CR33">2001</xref>; Guy et al. <xref ref-type="bibr" rid="CR76">2001</xref>). These mice can be crossed with transgenic mice carrying a tissue- or cell type-specific Cre to achieve spatial or temporal deletion of <italic>Mecp2</italic>. Studies using these mice have greatly informed <italic>Mecp2</italic> function both within the CNS and in peripheral tissues. Neuronal dysfunction was once considered the only cause of RTT, despite <italic>MECP2</italic>’s expression in glial cells. Crossing <italic>Mecp2-</italic>floxed mice to mice with a glial-specific <italic>GFAP</italic>-Cre transgene achieved targeted deletion of <italic>Mecp2</italic> in astrocytes. These mice developed RTT-like symptoms including decreased body weight, hindlimb clasping, and irregular breathing, demonstrating that glial <italic>Mecp2</italic> deficiency could produce some RTT symptoms (Lioy et al. <xref ref-type="bibr" rid="CR123">2011</xref>). Additionally, liver-targeted deletion of <italic>Mecp2</italic> was achieved by crossing <italic>Mecp2-</italic>floxed mice to mice expressing Cre under the control of an <italic>Albumin</italic> promoter (<italic>Alb</italic>-Cre). The resulting mice develop fatty liver disease and dyslipidemia, implicating <italic>MECP2</italic> in the regulation of lipid metabolism in non-CNS tissues (Kyle et al. <xref ref-type="bibr" rid="CR112">2016</xref>). Since transgenic mice have been engineered to express Cre from many diverse cell types, continued studies are likely to achieve a thorough understanding of <italic>Mecp2’s</italic> role in a variety of tissues and cell types.</p>
<p id="Par18">A significant question in RTT research concerns phenotypic reversibility: Since RTT patients do not display neuronal death, it is possible that <italic>Mecp2-</italic>deficient cells can be repaired. In a milestone study, a mouse model was engineered to contain a transcriptional STOP cassette flanked by <italic>lox</italic>P, which was inserted into the endogenous <italic>Mecp2</italic> gene (Guy et al. <xref ref-type="bibr" rid="CR77">2007</xref>). These ‘<italic>FloxedStop’</italic> mice were crossed with mice expressing a ubiquitous Cre-ER transgene. This strategy allowed for <italic>Mecp2</italic> to remain silenced in mice until Cre could be activated with injection of tamoxifen. ‘<italic>FloxedStop’</italic> male mice were identical to <italic>Mecp2-</italic>null mice, developed RTT-like symptoms and had a shortened lifespan. Following phenotype onset, tamoxifen was administered systemically, removing the <italic>loxP-</italic>STOP-<italic>loxP</italic> cassette and restoring <italic>Mecp2</italic> expression to 80% of normal levels. Remarkably, restoring <italic>MECP2</italic> expression reversed neurological symptoms and normalized lifespan (Guy et al. <xref ref-type="bibr" rid="CR77">2007</xref>). This key study demonstrated that <italic>Mecp2-</italic>induced pathology is not permanent and symptom reversal may be possible in human patients.</p>
<p id="Par19">Given <italic>MECP2</italic>’s high expression levels, its global DNA-binding affinity, and its multitude of proposed binding partners and functions, it is unsurprising that <italic>Mecp2-</italic>deficiency results in a myriad of dysregulated pathways. <italic>MECP2</italic> has been implicated in neuronal maintenance (Kishi and Macklis <xref ref-type="bibr" rid="CR100">2004</xref>; Guy et al. <xref ref-type="bibr" rid="CR78">2011</xref>), glial cell function (Ballas et al. <xref ref-type="bibr" rid="CR11">2009</xref>), neurotransmitter signaling (Goffin and Zhou <xref ref-type="bibr" rid="CR68">2012</xref>), growth factor signaling (Itoh et al. <xref ref-type="bibr" rid="CR90">2007</xref>), lipid metabolism (Buchovecky et al. <xref ref-type="bibr" rid="CR23">2013</xref>), oxidative stress (Großer et al. <xref ref-type="bibr" rid="CR74">2012</xref>), and more. Current preclinical research follows two approaches: targeting pathways downstream of <italic>MECP2</italic> or directly targeting <italic>MECP2</italic> and its protein product (Fig. <xref ref-type="fig" rid="Fig3">3</xref>).</p>
<p id="Par20">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Treatment options in RTT either directly target <italic>MECP2</italic> mutation or target pathways downstream of <italic>MECP2</italic>. Treatment options are further divided within these two groups</p></caption><graphic id="d29e2129" xlink:href="335_2019_9793_Fig3_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec4">
<title>Using mouse models to develop therapeutics for RTT targeting pathways downstream of <italic>Mecp2</italic></title>
<p id="Par21">The first approach of recognizing components that lie in pathways downstream of <italic>MECP2</italic> has identified many targets with the potential for treatment. Pharmacological therapeutics for targets downstream of <italic>MECP2</italic> can be repurposed to improve neurotransmitter signaling, growth factor signaling, and metabolism (Table <xref ref-type="table" rid="Tab3">3</xref>). Importantly, several of these treatments ameliorated symptoms in <italic>Mecp2-</italic>mutant mice and have spawned clinical trials in patients. However, these strategies revealed several limitations. First, because the precise functions of <italic>MECP2</italic> are still unknown, identifying the pathways it regulates, especially those which may be subtly changed in the absence of <italic>MECP2</italic>, is difficult. Another challenge is specificity: <italic>MECP2</italic> is recruited to DNA methylation signals, which are highly cell-specific (Cedar <xref ref-type="bibr" rid="CR27">1988</xref>; Deaton et al. <xref ref-type="bibr" rid="CR49">2011</xref>). Therefore, the genes <italic>MECP2</italic> regulates will likely vary based on methylation status in different cell types. Consistently, a recent study found that gene misregulation within subtypes of neurons in <italic>Mecp2</italic> mutant mice is highly dependent on cell type-specific epigenetic marks (Renthal et al. <xref ref-type="bibr" rid="CR166">2018</xref>). Finally, it is difficult to discern which pathways are affected as the primary result of <italic>MECP2</italic> loss and which are secondary effects farther downstream that will likely have less value as therapeutic targets. Nevertheless, advances in molecular biology techniques are making it easier to circumvent these issues. For example, single-cell RNA sequencing can identify genes misregulated in individual <italic>Mecp2</italic>-deficient cells and chromatin immunoprecipitation of <italic>MECP2</italic>’s known binding partners could identify its direct transcriptional targets in individual cells. Here, we highlight preclinical treatments targeting pathways downstream of <italic>Mecp2</italic> which have led to clinical trials in RTT patients.</p>
<p id="Par22">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Preclinical treatments targeting pathways downstream of <italic>Mecp2</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Treatment</th><th align="left">Mechanism</th><th align="left">Mouse model</th><th align="left">Prolong lifespan</th><th align="left">Improved phenotype</th><th align="left">References</th><th align="left">Clinical trial</th></tr></thead><tbody><tr><td align="left" colspan="6">
<bold>Neurotransmitter signaling</bold>
</td><td align="left"></td></tr><tr><td align="left">Citalopram</td><td align="left">Serotonin reuptake blocker</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Improved sensitivity to carbon dioxide exposure</td><td align="left">Toward et al. (<xref ref-type="bibr" rid="CR192">2013</xref>)</td><td align="left">–</td></tr><tr><td align="left">8-OH-DPAT</td><td align="left">Serotonin 1a agonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas</td><td align="left">Abdala et al. (<xref ref-type="bibr" rid="CR1">2010</xref>)</td><td align="left">–</td></tr><tr><td align="left">F15599</td><td align="left">Serotonin 1a agonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas and improves breathing irregularity</td><td align="left">Levitt et al. (<xref ref-type="bibr" rid="CR118">2013</xref>)</td><td align="left">–</td></tr><tr><td align="left">Sarizotan</td><td align="left">Serotonin 1a agonist &amp; dopamine D2-like receptor</td><td align="left"><p>
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</p><p>
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</p><p>
<italic>Mecp2</italic>
<sup><italic>tm1.1Jtc</italic></sup>
</p></td><td align="left">NT</td><td align="left">Reduced apneas and improved breathing irregularity</td><td align="left">Abdala et al. (<xref ref-type="bibr" rid="CR2">2014</xref>)</td><td align="left">Y</td></tr><tr><td align="left">LP-211</td><td align="left">Serotonin 7 receptor agonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved overall health, memory and anxiety</td><td align="left">De Filippis et al. (<xref ref-type="bibr" rid="CR46">2014</xref>)</td><td align="left">–</td></tr><tr><td align="left">Levodopa</td><td align="left">Dopaminergic stimulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Improved motor activity</td><td align="left">Szczesna et al. (<xref ref-type="bibr" rid="CR186">2014</xref>)</td><td align="left">–</td></tr><tr><td align="left">Ketamine</td><td align="left">NMDA receptor antagonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved startle response</td><td align="left">Kron et al. (<xref ref-type="bibr" rid="CR107">2012</xref>)</td><td align="left">Y</td></tr><tr><td align="left">Ketamine</td><td align="left">NMDA receptor antagonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Improved limb clasping, motor coordination and reduced apneas</td><td align="left">Patrizi et al. (<xref ref-type="bibr" rid="CR158">2016</xref>)</td><td align="left">Y</td></tr><tr><td align="left">NO-711</td><td align="left">GABA reuptake blocker</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas</td><td align="left">Abdala et al. (<xref ref-type="bibr" rid="CR1">2010</xref>)</td><td align="left">–</td></tr><tr><td align="left">Benzodiazepine diazepam</td><td align="left">GABA reuptake blocker</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas</td><td align="left">Abdala et al. (<xref ref-type="bibr" rid="CR1">2010</xref>)</td><td align="left">–</td></tr><tr><td align="left">L-838,417</td><td align="left">GABA reuptake blocker</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas</td><td align="left">(Abdala et al. <xref ref-type="bibr" rid="CR1">2010</xref>)</td><td align="left">–</td></tr><tr><td align="left">Tiagabine</td><td align="left">GABA reuptake blocker</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">No improvement</td><td align="left">El-Khoury et al. (<xref ref-type="bibr" rid="CR58">2014</xref>)</td><td align="left">–</td></tr><tr><td align="left">THIP</td><td align="left">GABA receptor agonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Improved motor function, social behavior, and reduced apneas</td><td align="left">Zhong et al. (<xref ref-type="bibr" rid="CR207">2016</xref>)</td><td align="left">–</td></tr><tr><td align="left">Mirtazapine</td><td align="left">GABA release promoter</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Improved overall healthy, neuronal morphology, dendritic spine number, anxiety</td><td align="left">Bittolo et al. (<xref ref-type="bibr" rid="CR18">2016</xref>)</td><td align="left">–</td></tr><tr><td align="left">VUO462807</td><td align="left">mGlu<sub>5</sub> positive allosteric modulator</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">N</td><td align="left">Improved motor function and limb clasping</td><td align="left">Gogliotti et al. (<xref ref-type="bibr" rid="CR69">2016</xref>)</td><td align="left">–</td></tr><tr><td align="left">VU0422288</td><td align="left">mGlu<sub>7</sub> positive allosteric modulator</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas, improves learning and memory</td><td align="left">Gogliotti et al. (<xref ref-type="bibr" rid="CR70">2017</xref>)</td><td align="left">–</td></tr><tr><td align="left">CTEP</td><td align="left">mGluR<sub>5</sub> negative allosteric modulator</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Reduced apneas, improved memory</td><td align="left">Tao et al. (<xref ref-type="bibr" rid="CR188">2016</xref>)</td><td align="left">–</td></tr><tr><td align="left">Acetyl-L-carnitine</td><td align="left">Acetyl group donor</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved weight gain, motor activity and memory</td><td align="left">Schaevitz et al. (<xref ref-type="bibr" rid="CR174">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">Acetyl-L-carnitine</td><td align="left">Acetyl group donor</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved weight gain, motor activity and memory</td><td align="left">Schaevitz et al. (<xref ref-type="bibr" rid="CR174">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">Choline</td><td align="left">ACh</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor coordination and activity</td><td align="left">Nag and Berger-Sweeney (<xref ref-type="bibr" rid="CR143">2007</xref>)</td><td align="left">–</td></tr><tr><td align="left">Choline</td><td align="left">ACh</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor activity</td><td align="left">Ricceri et al. (<xref ref-type="bibr" rid="CR168">2011</xref>)</td><td align="left">–</td></tr><tr><td align="left">Choline</td><td align="left">ACh</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor coordination, anxiety and social behavior</td><td align="left">Chin et al. (<xref ref-type="bibr" rid="CR36">2018</xref>)</td><td align="left">–</td></tr><tr><td align="left">D-NAC</td><td align="left">Dendrimer-conjugated N-acetyl cysteine</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Improved overall health, limb clasping</td><td align="left">Nance et al. (<xref ref-type="bibr" rid="CR148">2017</xref>)</td><td align="left">–</td></tr><tr><td align="left">Desipramine</td><td align="left">Norepinephrine reuptake inhibitor</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Improved breathing irregularities</td><td align="left">Roux et al. (<xref ref-type="bibr" rid="CR170">2007</xref>)</td><td align="left">Y</td></tr><tr><td align="left">Desipramine</td><td align="left">Norepinephrine reuptake inhibitor</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Reduced apneas</td><td align="left">Zanella et al. (<xref ref-type="bibr" rid="CR205">2008</xref>)</td><td align="left">Y</td></tr><tr><td align="left">Clenbuterol</td><td align="left">B2-adrenergic receptor agonist</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Improved motor coordination and breathing irregularities</td><td align="left">Mellios et al. (<xref ref-type="bibr" rid="CR134">2014</xref>)</td><td align="left">–</td></tr><tr><td align="left">D-cycloserine</td><td align="left">D-alanine analog</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">No improvement</td><td align="left">Na et al. (<xref ref-type="bibr" rid="CR142">2017</xref>)</td><td align="left">–</td></tr><tr><td align="left" colspan="6">
<bold>Growth factor signaling</bold>
</td><td align="left"></td></tr><tr><td align="left">CX546</td><td align="left">Ampakine (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved breathing irregularity</td><td align="left">Ogier et al. (<xref ref-type="bibr" rid="CR152">2007</xref>)</td><td align="left">–</td></tr><tr><td align="left">Fingolimod</td><td align="left">Sphingosine-1 phosphate receptor (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor activity</td><td align="left">Deogracias et al. (<xref ref-type="bibr" rid="CR51">2012</xref>)</td><td align="left">Y</td></tr><tr><td align="left">CPT157633</td><td align="left">PTP1B inhibitor (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Reduced limb clasping, partially improved motor activity</td><td align="left">Krishnan et al. (<xref ref-type="bibr" rid="CR106">2015</xref>)</td><td align="left">–</td></tr><tr><td align="left">LM22A-4</td><td align="left">TrkB agonist (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved breathing irregularity</td><td align="left">Schmid et al. (<xref ref-type="bibr" rid="CR176">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">7,8-DHF</td><td align="left">TrKB agonist (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">Y</td><td align="left">Improved motor activity and breathing irregularities</td><td align="left">Johnson et al. (<xref ref-type="bibr" rid="CR94">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">LM22A-4</td><td align="left">TrkB agonist (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced apneas</td><td align="left">Kron et al. (<xref ref-type="bibr" rid="CR108">2014</xref>)</td><td align="left">–</td></tr><tr><td align="left">LM22A-4</td><td align="left">TrkB agonist (BDNF)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved memory</td><td align="left">Li et al. (<xref ref-type="bibr" rid="CR120">2017</xref>)</td><td align="left">–</td></tr><tr><td align="left">IGF-1</td><td align="left">IGF-1</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">Y</td><td align="left">Improves motor activity, breathing irregularities, increased brain size</td><td align="left">Tropea et al. (<xref ref-type="bibr" rid="CR193">2009</xref>)</td><td align="left">Y</td></tr><tr><td align="left">PEG-IGF-1</td><td align="left">Slow release IGF-1</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">No improvement</td><td align="left">Pitcher et al. (<xref ref-type="bibr" rid="CR160">2013</xref>)</td><td align="left">–</td></tr><tr><td align="left">RhIGF01</td><td align="left">Recombinant human IGF1-1</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Improves motor activity, breathing irregularities, social behavior and anxiety</td><td align="left">Castro et al. (<xref ref-type="bibr" rid="CR26">2014</xref>)</td><td align="left">Y</td></tr><tr><td align="left" colspan="7">
<bold>Metabolism</bold>
</td></tr><tr><td align="left">Diet restriction</td><td align="left">Caloric deficit</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor activity and anxiety</td><td align="left">Mantis et al. (<xref ref-type="bibr" rid="CR130">2009</xref>)</td><td align="left">–</td></tr><tr><td align="left">Statins</td><td align="left">Cholesterol-lowering medication</td><td align="left"><p>
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</p><p>
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</p></td><td align="left">Y</td><td align="left">Improved overall health, motor coordination, motor activity, serum lipids and liver lipids</td><td align="left">Buchovecky et al. (<xref ref-type="bibr" rid="CR23">2013</xref>)</td><td align="left">Y</td></tr><tr><td align="left">Dietary triheptanoin</td><td align="left">Energy use (mitochondria)</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">Y</td><td align="left">Improved motor coordination, social behavior, insulin sensitivity, metabolic homeostasis</td><td align="left">Park et al. (<xref ref-type="bibr" rid="CR156">2014</xref>)</td><td align="left">Y</td></tr><tr><td align="left">Trolox</td><td align="left">Vitamin E derivative</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Blood glucose levels normalized, improved response to hypoxia</td><td align="left">Janc et al. (<xref ref-type="bibr" rid="CR92">2016</xref>)</td><td align="left">–</td></tr><tr><td align="left">Corticosterone</td><td align="left">Glucocorticoid activation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Decreased lifespan</td><td align="left">Worsened motor activity</td><td align="left">Braun et al. (<xref ref-type="bibr" rid="CR20">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">Corticosterone</td><td align="left">Glucocorticoid activation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor activity</td><td align="left">De Filippis et al. (<xref ref-type="bibr" rid="CR44">2013</xref>)</td><td align="left">–</td></tr><tr><td align="left">RU486</td><td align="left">Glucocorticoid repression</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">No</td><td align="left">Delayed progression of symptoms, improved motor activity</td><td align="left">Braun et al. (<xref ref-type="bibr" rid="CR20">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">Curcumin</td><td align="left">Anti-oxidant, anti-inflammatory</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">NT</td><td align="left">Panighini et al. (<xref ref-type="bibr" rid="CR155">2013</xref>)</td><td align="left">–</td></tr><tr><td align="left">Insulin</td><td align="left">Glucose signaling</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Decreased lifespan</td><td align="left">No improvement</td><td align="left">Pitcher et al. (<xref ref-type="bibr" rid="CR160">2013</xref>)</td><td align="left">–</td></tr><tr><td align="left" colspan="7">
<bold>Other</bold>
</td></tr><tr><td align="left">Zoledronic acid</td><td align="left">Anti-osteoclastic</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Increased bone volume and connectivity</td><td align="left">Shapiro et al. (<xref ref-type="bibr" rid="CR181">2010</xref>)</td><td align="left">–</td></tr><tr><td align="left">Cannabidivarin</td><td align="left">Phytocannabinoid</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved overall health, motor activity and social behavior</td><td align="left">Vigli et al. (<xref ref-type="bibr" rid="CR197">2018</xref>)</td><td align="left">–</td></tr><tr><td align="left">CNF1</td><td align="left">RhoGTPase</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor activity</td><td align="left">De Filippis et al. (<xref ref-type="bibr" rid="CR43">2012</xref>)</td><td align="left">–</td></tr><tr><td align="left">CNF1</td><td align="left">Rho GTPase</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Hzo</italic></sup>
</td><td align="left">NT</td><td align="left">Improved mitochondrial dysfunction and memory</td><td align="left">De Filippis et al. (<xref ref-type="bibr" rid="CR47">2015</xref>)</td><td align="left">–</td></tr><tr><td align="left" colspan="7">
<bold>Non-pharmacological</bold>
</td></tr><tr><td align="left">Enriched environment</td><td align="left">Environmental modulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Pplt</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor coordination</td><td align="left">Kondo et al. (<xref ref-type="bibr" rid="CR103">2008</xref>)</td><td align="left">–</td></tr><tr><td align="left">Enriched environment</td><td align="left">Environmental modulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">NT</td><td align="left">Improved motor activity</td><td align="left">Nag et al. (<xref ref-type="bibr" rid="CR144">2009</xref>)</td><td align="left">–</td></tr><tr><td align="left">Enriched environment</td><td align="left">Environmental modulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Jae</italic></sup>
</td><td align="left">N</td><td align="left">Improved motor coordination and activity</td><td align="left">Lonetti et al. (<xref ref-type="bibr" rid="CR126">2010</xref>)</td><td align="left">–</td></tr><tr><td align="left">Enriched environment</td><td align="left">Environmental modulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1Pplt</italic></sup>
</td><td align="left">NT</td><td align="left">Reduced anxiety</td><td align="left">Kondo et al. (<xref ref-type="bibr" rid="CR104">2016</xref>)</td><td align="left">–</td></tr><tr><td align="left">Forniceal deep brain stimulation</td><td align="left">Neural circuit stimulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">NT</td><td align="left">Improved memory</td><td align="left">Hao et al. (<xref ref-type="bibr" rid="CR85">2015</xref>)</td><td align="left">–</td></tr><tr><td align="left">Bone marrow transplantation</td><td align="left">Brain microglia repopulation</td><td align="left">
<italic>Mecp2</italic>
<sup><italic>tm1.1Bird</italic></sup>
</td><td align="left">Y</td><td align="left">Reduced apneas, improved breathing irregularities, improved locomotor activity</td><td align="left">Derecki et al. (<xref ref-type="bibr" rid="CR52">2012</xref>)</td><td align="left">–</td></tr></tbody></table><table-wrap-foot><p>Treatment strategies are divided into those influencing neurotransmitter signaling, growth factor signaling, metabolism, other pharmacological treatments, and non-pharmacological treatments. In prolong lifespan column, <italic>Y</italic> yes, <italic>N</italic> no, <italic>NT</italic> not tested. In clinical trial column, <italic>Y</italic> yes, –: not yet tested</p></table-wrap-foot></table-wrap>
</p>
<sec id="Sec5">
<title>Potential treatments targeting neurotransmitter signaling</title>
<p id="Par23">A prominent feature of RTT and <italic>Mecp2</italic>-mutant mouse models is the reduction in the number and length of dendrites (Armstrong <xref ref-type="bibr" rid="CR8">1992</xref>). Since dendrites receive electrical signals and neurotransmitters from pre-synaptic neurons, a neurotransmitter signaling defect was proposed in RTT. In support of this idea, dysfunction in dopamine (Wenk <xref ref-type="bibr" rid="CR200">1995</xref>), serotonin (Paterson et al. <xref ref-type="bibr" rid="CR157">2005</xref>; Ohno et al. <xref ref-type="bibr" rid="CR153">2016</xref>), norepinephrine (Viemari <xref ref-type="bibr" rid="CR196">2005</xref>; Santos et al. <xref ref-type="bibr" rid="CR173">2010</xref>), glutamate (Chao et al. <xref ref-type="bibr" rid="CR32">2010</xref>; Abdala et al. <xref ref-type="bibr" rid="CR3">2016</xref>), and NMDA signaling (Katz et al. <xref ref-type="bibr" rid="CR96">2016</xref>; Patrizi et al. <xref ref-type="bibr" rid="CR158">2016</xref>) has been observed in <italic>Mecp2</italic>-mutant mice. Treatments that target these pathways have shown varied effects in mice, and a few have been tested in clinical trials. Desipramine, a norepinephrine reuptake inhibitor, improved breathing irregularities and apneas in <italic>Mecp2-</italic>mutant mice (Roux et al. <xref ref-type="bibr" rid="CR170">2007</xref>; Zanella et al. <xref ref-type="bibr" rid="CR205">2008</xref>). However, a clinical trial found no clinical improvements in RTT patients treated with this drug (Mancini et al. <xref ref-type="bibr" rid="CR129">2018</xref>). In contrast, sarizotan, a serotonin 1a agonist and dopamine D2-like receptor, reduced breathing apneas by 15–30% in <italic>Mecp2-</italic>mutant mice but had no effect on motor activity (Abdala et al. <xref ref-type="bibr" rid="CR2">2014</xref>). As a result, it is currently being tested for its efficacy in improving respiratory symptoms in RTT (NCT02790034).</p>
<p id="Par24">Finally, ketamine, an NMDA receptor agonist, was tested in two different laboratories for its therapeutic potential in RTT (Kron et al. <xref ref-type="bibr" rid="CR107">2012</xref>; Patrizi et al. <xref ref-type="bibr" rid="CR158">2016</xref>). These preclinical studies showed that low-dose ketamine could increase activity in the cortical network while decreasing synaptic excitability in the brainstem network, targeting a possible imbalance in neuronal activity throughout the <italic>Mecp2-</italic>mutant brain. Treatment with ketamine improved limb clasping, motor coordination, and breathing apneas in <italic>Mecp2-</italic>mutant mice. The safety of ketamine is currently being assessed in RTT patients (NCT03633058).</p>
</sec>
<sec id="Sec6">
<title>Growth factor signaling as a treatment for RTT</title>
<p id="Par25">Early studies of <italic>MECP2</italic> identified BDNF as one of its transcriptional targets (Chen et al. <xref ref-type="bibr" rid="CR34">2003</xref>). BDNF is a member of the neurotrophin family of growth factors, which binds to tropomyosin-related kinase B (TrkB) to stimulate signaling cascades involved in neurite outgrowth, synaptic function, and neuronal differentiation (Amaral and Pozzo-Miller <xref ref-type="bibr" rid="CR5">2007</xref>). In RTT patients and <italic>Mecp2-</italic>mutant mice, brain <italic>Bdnf</italic> expression is drastically reduced (Chang et al. <xref ref-type="bibr" rid="CR31">2006</xref>; Deng et al. <xref ref-type="bibr" rid="CR50">2007</xref>). However, direct administration of BDNF is not a feasible treatment option because it is unable to cross the blood–brain barrier (BBB). However, fingolimod (FTY720), a sphingosine-1 phosphate analog, has been shown to partially increase BDNF levels and improve motor activity in <italic>Mecp2-</italic>mutant mice (Deogracias et al. <xref ref-type="bibr" rid="CR51">2012</xref>). Fingolimod is currently being assessed for its safety and efficacy in patients (NCT02061137).</p>
<p id="Par26">Insulin-like growth factor-1 (IGF) binds to the IGF-1 receptor (IGF-1R), activating a signaling cascade similar to the BDNF receptor TrkB. IGF-1 is also transcriptionally regulated by <italic>MECP2</italic> (Itoh et al. <xref ref-type="bibr" rid="CR90">2007</xref>), but unlike BDNF, it can cross the BBB, increasing its therapeutic potential (Baker et al. <xref ref-type="bibr" rid="CR10">2005</xref>). IGF-1 signaling is involved in neuronal survival, neural outgrowth, and synapse formation (D’Ercole et al. <xref ref-type="bibr" rid="CR41">1996</xref>). It has been implicated as a promising therapeutic in cancer, diabetes, and ALS.</p>
<p id="Par27"><italic>Mecp2-</italic>mutant mice treated with IGF-1 showed improved locomotor function, breathing irregularities, and extended lifespan. IGF-1 also increased the brain weight of mutant mice while restoring neural spine density in the motor cortex and improving excitatory synaptic transmission in sensorimotor cortex neurons (Tropea et al. <xref ref-type="bibr" rid="CR193">2009</xref>). Importantly, full-length IGF-1 is already an approved treatment in North America used to treat growth failure in children. A phase 1 clinical trial in RTT patients found no adverse effects of recombinant human IGF-1 (rhIGF-1) (Khwaja et al. <xref ref-type="bibr" rid="CR99">2014</xref>). However, subsequent clinical trials found it produced no significant improvement of RTT symptoms (O’Leary et al. <xref ref-type="bibr" rid="CR151">2018</xref>).</p>
<p id="Par28">Recently, a synthetic analog derived from IGF-1, NNZ-2566 (Trofinetide) was developed which inhibits neuroinflammation, restores glial function, corrects synaptic deficits, and regulates oxidative stress response (Deacon et al. <xref ref-type="bibr" rid="CR48">2015</xref>). When administered to mice with Fragile X syndrome, NNZ-2566 drastically improved their aberrant symptoms (Ligsay and Hagerman <xref ref-type="bibr" rid="CR121">2016</xref>). A phase 2 clinical trial of NNZ-2566 in RTT patients showed that treatment improved overall health, neurobehavioral and motor symptoms. These promising results enabled a phase 3 clinical trial that is currently recruiting patients (NCT02715115).</p>
</sec>
<sec id="Sec7">
<title>Metabolic defects in RTT can be therapeutically targeted</title>
<p id="Par29">Modifiers of <italic>MECP2</italic> have implicated neurite outgrowth and energy homeostasis in altering phenotypic outcome in human patients (Artuso et al. <xref ref-type="bibr" rid="CR9">2011</xref>; Pizzo et al. <xref ref-type="bibr" rid="CR162">2018</xref>). Modifiers are also being identified and validated by carrying out modifier screens in a mouse model (Buchovecky et al. <xref ref-type="bibr" rid="CR23">2013</xref>). In a modifier screen, unbiased random mutation identifies key genes that can change a phenotype of interest, allowing the model to reveal important pathways of interest. Such an approach was applied to identify novel therapeutic targets in RTT; ethylnitrosourea (ENU), a mouse supermutagen, was used to induce mutations in male mice, which were then bred to females carrying a mutant <italic>Mecp2</italic>. Male mice inheriting mutant <italic>Mecp2</italic> would normally become very ill and die. Dominant second site mutations that could improve the health and neurological phenotype of the <italic>Mecp2</italic> mutant males were then identified molecularly (Buchovecky et al. <xref ref-type="bibr" rid="CR23">2013</xref>). One suppressor of disease was a nonsense mutation in a rate-limiting enzyme in cholesterol synthesis—a pathway that had not previously been associated with RTT.</p>
<p id="Par30">The identification of this modifier locus led to additional studies that revealed lipid metabolism was severely perturbed in <italic>Mecp2</italic>-mutant mice. Prior to symptom onset, brain cholesterol was already markedly elevated in <italic>Mecp2-</italic>mutant mice, and cholesterol and triglycerides were elevated in the serum and liver. Remarkably, lipid-lowering statin drugs regulated lipid levels, ameliorated motor symptoms, and extended lifespan in mice (Buchovecky et al. <xref ref-type="bibr" rid="CR23">2013</xref>). Furthermore, elevated lipids have also been observed in a subset of RTT patients, indicating that repurposing of statin drugs may be a viable treatment option to benefit patients (Justice et al. <xref ref-type="bibr" rid="CR95">2013</xref>; Segatto et al. <xref ref-type="bibr" rid="CR178">2014</xref>). Abnormalities in cholesterol homeostasis are associated with many neurological diseases (Tint et al. <xref ref-type="bibr" rid="CR191">1994</xref>; Puglielli et al. <xref ref-type="bibr" rid="CR164">2003</xref>; Bi and Liao <xref ref-type="bibr" rid="CR15">2010</xref>; Berry-Kravis et al. <xref ref-type="bibr" rid="CR13">2015</xref>), and therefore RTT is no exception. Importantly, these findings led to a clinical trial testing the efficacy and safety of statins in RTT patients (NCT02563860).</p>
<p id="Par31">Metabolic defects in RTT are not limited to cholesterol synthesis. Both RTT patients and <italic>Mecp2-</italic>mutant mouse models display abnormal mitochondrial structure and function (Eeg-Olofsson et al. <xref ref-type="bibr" rid="CR56">1988</xref>; Dotti et al. <xref ref-type="bibr" rid="CR53">1993</xref>; Kriaucionis et al. <xref ref-type="bibr" rid="CR105">2006</xref>; Gold et al. <xref ref-type="bibr" rid="CR71">2014</xref>). Mitochondria are organelles within cells that convert glucose into adenosine triphosphate (ATP), the energy currency of the cell. Importantly, compromised mitochondrial function can greatly affect cellular energy production. While mitochondria are necessary in all cells of the body, their role is especially important in tissues with high energy demands, such as nerves and muscle. RTT shares many features of mitochondrial diseases, including early symptomatic onset, developmental delay, neurological regression, poor muscle tone, seizures, and gastrointestinal issues (Schon and Manfredi <xref ref-type="bibr" rid="CR177">2003</xref>). Consistently, both RTT patients and <italic>Mecp2-</italic>mutant mice present with increased oxidative stress and decreased levels of mitochondrial enzymes (Haas et al. <xref ref-type="bibr" rid="CR80">1995</xref>; Kriaucionis et al. <xref ref-type="bibr" rid="CR105">2006</xref>; De Felice et al. <xref ref-type="bibr" rid="CR42">2009</xref>; Leoncini et al. <xref ref-type="bibr" rid="CR117">2011</xref>). In <italic>Mecp2-</italic>mutant mice, markers of oxidative stress increase with age, suggesting a progressive dysfunction in mitochondrial function (De Felice et al. <xref ref-type="bibr" rid="CR45">2014</xref>). Altogether, this suggests defects in mitochondrial energy production may be present in RTT. Importantly, mitochondrial energy production is tightly linked with cholesterol synthesis. Several steps in the biosynthesis of cholesterol require mitochondrial sources of ATP as an electron donor in oxygenation reactions. Thus, cholesterol perturbations may be linked with mitochondrial dysfunction in RTT.</p>
<p id="Par32">Interestingly, anaplerotic substances can replenish intermediate compounds in the energy production pathway, enhancing mitochondrial energy production. A diet supplemented with the anaplerotic triheptanoin reversed symptoms of some metabolic disorders by correcting energy production (Roe et al. <xref ref-type="bibr" rid="CR169">2002</xref>; Mochel et al. <xref ref-type="bibr" rid="CR136">2005</xref>). This strategy was adapted for use in mouse models of RTT. Strikingly, <italic>Mecp2</italic>-mutant mice fed a diet with triheptanoin supplementation showed improved mitochondrial morphology and improved energy production. This translated to improved motor coordination and increased lifespan in these mice. Two clinical trials investigating the efficacy of triheptanoin in improving seizures, muscle tone, and symptom improvement in RTT patients are currently in their early stages (NCT02696044 and NCT03059160).</p>
</sec>
</sec>
<sec id="Sec8">
<title>Using mouse models to develop therapies for RTT that directly target <italic>MECP2</italic></title>
<p id="Par33">Directly restoring <italic>MECP2</italic> is an attractive therapeutic strategy (Fig. <xref ref-type="fig" rid="Fig3">3</xref>) since all pathways downstream of <italic>MECP2</italic> could subsequently recover as well. However, the largest concern of these approaches is dosage. While lack of <italic>MECP2</italic> causes RTT, an abundance of <italic>MECP2</italic> causes <italic>MECP2</italic> duplication syndrome, a disorder characterized by neurological dysfunction, intellectual disability, and some RTT-like features (Van Esch et al. <xref ref-type="bibr" rid="CR195">2005</xref>). In mice, <italic>MECP2</italic> overexpression causes hypoactivity and seizures (Collins et al. <xref ref-type="bibr" rid="CR38">2004</xref>; Bodda et al. <xref ref-type="bibr" rid="CR19">2013</xref>). The amount of <italic>MECP2</italic> required to cause toxicity associated with overexpression has been debated, with some studies finding that 1.6 × normal levels of <italic>MECP2</italic> cause behavioral impairments in mice (Jugloff, 2008) and others finding that 2.4 × normal <italic>MECP2</italic> can be tolerated (Koerner et al. <xref ref-type="bibr" rid="CR102">2018</xref>). Despite this discrepancy, small deviations in <italic>MECP2</italic> levels in humans have been linked to milder neurological and psychiatric conditions including autism, intellectual disability, and lupus erythematosus. Thus, caution must be taken to provide enough <italic>MECP2</italic> per cell to impart a therapeutic benefit while reducing the risk of <italic>MECP2</italic> overexpression.</p>
<sec id="Sec9">
<title>Read-through compounds may facilitate the recovery of <italic>MECP2</italic> product</title>
<p id="Par34">One strategy involves directly targeting the <italic>MECP2</italic> mutation with small molecules known as translational read-through-inducing drugs (TRIDs). This is an attractive strategy for 35–40% of Rett syndrome patients who have nonsense mutations in <italic>MECP2</italic> that result in premature stop codons, which inhibit normal full-length protein expression (Neul et al. <xref ref-type="bibr" rid="CR149">2008</xref>). TRIDs permit read-through of premature stop codons by binding to ribosomes and impairing codon/anticodon recognition, allowing for the insertion of another amino acid in place of the stop codon (Nagel-Wolfrum et al. <xref ref-type="bibr" rid="CR145">2016</xref>). Notably, this causes a missense mutation rather than a nonsense mutation, which may impart less of a functional consequence on the protein product. Importantly, this strategy would increase <italic>MECP2</italic> in cells with the nonsense mutation, while avoiding increasing dosage in cells with normal <italic>MECP2</italic>. However, because TRIDs would create a mutated <italic>MECP2</italic> rather than a fully functional protein, this treatment strategy may only modestly improve symptoms in patients. An additional concern is nonsense mediated decay (NMD), a cellular process that facilitates the degradation of mRNA transcripts with premature stop codons because their translation could lead to mutated proteins with deleterious gain-of-function or dominant-negative effects (Conti and Izaurralde <xref ref-type="bibr" rid="CR39">2005</xref>). In mammalian cells, when a premature stop codon is located greater than 50–55 nucleotides away from an exon–exon junction, NMD is activated (Nagy and Maquat <xref ref-type="bibr" rid="CR146">1998</xref>; Kuzmiak and Maquat <xref ref-type="bibr" rid="CR111">2006</xref>). NMD naturally reduces the number of transcripts available for TRIDs (Linde et al. <xref ref-type="bibr" rid="CR122">2007</xref>). Therefore, TRIDs may not be a suitable treatment option for RTT patients with certain nonsense mutations which are prone to NMD as the best responders will have high levels of target transcript. However, the efficacy of NMD varies naturally between individuals (Nguyen et al. <xref ref-type="bibr" rid="CR150">2014</xref>) and patient transcript levels could be assayed to determine if they are candidates for TRID therapy.</p>
<p id="Par35">One class of TRIDs is aminoglycoside antibiotics, of which gentamicin is the most commonly studied. Gentamicin has been shown to suppress nonsense mutations and restore function protein in mouse models of Duchenne muscular dystrophy (DMD) (Barton-Davis et al. <xref ref-type="bibr" rid="CR12">1999</xref>), cystic fibrosis (CF) (Du et al. <xref ref-type="bibr" rid="CR54">2008</xref>), retinal degeneration (Guerin et al. <xref ref-type="bibr" rid="CR75">2008</xref>), and several other diseases. Importantly, clinical trials in DMD and CF patients have demonstrated gentamicin’s ability to restore protein products in a subset of patients, giving hope for the effectiveness of TRIDs in other diseases (Nagel-Wolfrum et al. <xref ref-type="bibr" rid="CR145">2016</xref>).</p>
<p id="Par36">Four of the most common RTT-causing mutations (R168X, R255X, R270X, R294X) result in premature stop mutations. In vitro studies have shown that read-through efficiency of gentamicin depends heavily on the context of the stop mutation, where gentamicin restored 22% of function <italic>MECP2</italic> in cells with R294X mutations and only 10% in cells with R168X (Brendel et al. <xref ref-type="bibr" rid="CR21">2011</xref>), possibly due to variable NMD. Increasing the concentration of gentamicin increased read-through efficiency and amounts of <italic>MECP2</italic> protein. However, these high levels of aminoglycosides could cause toxic side effects if administered over a long period of time (Popescu et al. <xref ref-type="bibr" rid="CR163">2010</xref>). Novel aminoglycosides and different TRIDs may impart higher read-through activity and lower toxicity (Brendel et al. <xref ref-type="bibr" rid="CR21">2011</xref>; Pitcher et al. <xref ref-type="bibr" rid="CR161">2015</xref>), though no in vivo tests with these novel compounds have performed in <italic>Mecp2</italic>-mutant mice.</p>
<p id="Par37">One new promising TRID is Ataluren, an orally bioavailable oxadiazole with no antibacterial activity and minimal off-target effects (Keeling et al. <xref ref-type="bibr" rid="CR97">2014</xref>). Ataluren restored 20% of normal functional protein in mouse models of DMD and CF, leading to clinical trials for both diseases. However, in both cases, Ataluren did not produce enough protein to see a significant benefit in patients (Kerem et al. <xref ref-type="bibr" rid="CR98">2014</xref>; McDonald et al. <xref ref-type="bibr" rid="CR133">2017</xref>). This may be a worthwhile avenue to pursue for RTT since even small increases in <italic>MECP2</italic> are associated with improved symptoms. Nonetheless, efforts are underway to improve the efficacy of TRIDs for suppression therapy, making them more likely to assist RTT patients.</p>
</sec>
<sec id="Sec10">
<title>Reactivating the silent X chromosome could restore endogenous <italic>MECP2</italic> to cells</title>
<p id="Par38">Through XCI, mammalian cells silence one X chromosome in each cell, allowing for dosage compensation of X-linked genes (Bhatnagar et al. <xref ref-type="bibr" rid="CR14">2014</xref>). XCI is initiated by the non-coding RNA <italic>Xist</italic>, which coats the inactive X chromosome (Xi) from which it is produced. On the active X (Xa), <italic>Tsix</italic> RNA blocks <italic>Xist</italic> upregulation. As <italic>MECP2</italic> is expressed on the X chromosome, one copy is silenced by XCI. Therefore, in cells of RTT patients where the mutated <italic>MECP2</italic> is on the Xa, a normal copy of <italic>MECP2</italic> lies dormant on the Xi.</p>
<p id="Par39">Interestingly, the silent state of the Xi is temporarily reversed during development and stem cell remodeling. In the case of X-linked diseases, identification of key molecular players involved in reactivation of the Xi could be repurposed to facilitate the re-expression of its genes. Using this strategy to target <italic>MECP2</italic> could provide a viable treatment option for RTT patients (Vacca et al. <xref ref-type="bibr" rid="CR194">2016</xref>). This is an attractive strategy for RTT because patient cells could use their own regulatory functions to control <italic>MECP2</italic> expression. However, sex chromosome dosage is an important developmental process and reactivating the second X chromosome may lead to a pathological level of expression for other X chromosome loci. Ideally, these strategies will aim to target the <italic>MECP2</italic> gene or its local vicinity alone. Additionally, the Xi can be difficult to reactivate due to multiple mechanisms of epigenetic silencing and attempting to disengage these processes could disrupt epigenetic patterns throughout the genome which could cause adverse long-term effects. Finally, because RTT patients are heterozygous mosaics for <italic>MECP2</italic> mutation, approximately half of their cells already express a normal copy of <italic>MECP2</italic>. Thus, Xi reactivation will lead to 2x the normal amount of <italic>MECP2</italic> in these cells. In patients carrying mutations that only reduce efficiency of <italic>MECP2</italic> rather than destroy its function, Xi reactivation will lead to anywhere from 1 to 2x the normal amount of <italic>MECP2</italic> in some cells. This could lead to symptoms associated with overexpression of <italic>MECP2</italic>. Therefore, Xi reactivation will need to be adapted to target only <italic>MECP2</italic> or its local vicinity, and may only be a practical treatment option for patients who have loss-of-function mutations in <italic>MECP2</italic>.</p>
<p id="Par40">One group reactivated the Xi using an antisense oligonucleotide to 5-aza-2′-deoxycytidine (Aza), a DNA methylation inhibitor, in a mouse with an <italic>Xist</italic> deletion on one chromosome and <italic>Mecp2</italic>-GFP on the other. This ensured that <italic>Mecp2-</italic>GFP was silenced in almost all cells. Treatment resulted in a great increase in GFP expression, indicating that <italic>Mecp2</italic> could be targeted by Xi reactivation tools (Carrette et al. <xref ref-type="bibr" rid="CR24">2017</xref>). Recently, a heterozygous female mouse was engineered with a mutation of <italic>Tsix</italic> on one chromosome and a null mutation of <italic>Mecp2</italic> on the other, directing the preferential expression of the chromosome with the mutated <italic>Mecp2</italic> (Carrette et al. <xref ref-type="bibr" rid="CR25">2018</xref>). This strategy achieved a <italic>Mecp2</italic>-null female mouse with all cells expressing the same Xa. Additionally, this group found that while <italic>Mecp2</italic>-null females had a shortened lifespan, a 5% increase in <italic>MECP2</italic> levels increased the lifespan by 50%, and a 10–20% increase in <italic>MECP2</italic> restored a normal lifespan (Carrette et al. <xref ref-type="bibr" rid="CR25">2018</xref>). Thus, small increases in <italic>MECP2</italic> can have great positive impacts on life expectancy. However, as a global inhibitor of methylation, Aza is toxic when administered over a long time course. Ongoing screens aim to identify new molecules to induce Xi reactivation that can be further tested and optimized for treatment (Bhatnagar et al. <xref ref-type="bibr" rid="CR14">2014</xref>; Minkovsky et al. <xref ref-type="bibr" rid="CR135">2015</xref>; Sripathy et al. <xref ref-type="bibr" rid="CR185">2017</xref>). Importantly, the unique mice designed in these studies will provide an excellent avenue to test candidate Xi-reactivating drugs specifically for the treatment of RTT.</p>
</sec>
<sec id="Sec11">
<title>Gene therapy</title>
<p id="Par41">A final potential avenue of treatment for RTT involves introducing a normal copy of <italic>MECP2</italic> into cells by gene therapy. Gene therapy is a promising approach for the treatment of many disorders and has been successful in reversing symptoms in mouse models of CF, hemophilia, Hunter syndrome, diabetes, obesity, ALS, and more. Recently, the first targeted gene therapy treatment was approved in North America to treat patients with Lever’s congenital amaurosis, a rare inherited eye disease (Kumaran et al. <xref ref-type="bibr" rid="CR110">2018</xref>).</p>
<p id="Par42">To treat RTT, gene therapy approaches must utilize an appropriate vector able to cross the BBB and transduce many cells in the CNS, and able to maintain stable long-term expression of the exogenously derived <italic>MECP2</italic>. Additionally, strategies must be developed to avoid transgene repression and avoid overexpression of <italic>MECP2</italic>. Like Xi reactivation, gene therapy targets all cells regardless of <italic>MECP2</italic> mutation status. Thus, cells expressing normal <italic>MECP2</italic> will have 2x the normal level of the protein leading to potential toxic effects of <italic>MECP2</italic> overexpression. An additional concern of gene therapy is that high viral titres are often needed to infect a large proportion of cells, but cells that inadvertently receive more than one viral particle, and hence more than one copy of <italic>MECP2</italic>, would be overburdened. Strategies to circumvent these issues could supply a factor such as an siRNA to suppress endogenous <italic>MECP2</italic> so that only the transgenic <italic>MECP2</italic> is expressed (Gadalla et al. <xref ref-type="bibr" rid="CR61">2011</xref>). However, this would require the transgenic <italic>MECP2</italic> to possess a seamless promoter to completely mimic endogenous gene expression. MicroRNAS (miRNAs) have been used to control exogenous transgene expression by mediating the degradation of transgene mRNAs in a tissue-specific manner and may be beneficial in RTT gene therapy approaches to limit off-target toxicity (Geisler and Fechner <xref ref-type="bibr" rid="CR66">2016</xref>).</p>
<p id="Par43">Recombinant adeno-associated virus (AAV) vectors have been used in preclinical gene therapy studies for their ability to cross the BBB, infect neurons, and mediate stable long-term expression of the transgene without inflammation or toxicity (Gonçalves <xref ref-type="bibr" rid="CR72">2005</xref>; Foust et al. <xref ref-type="bibr" rid="CR60">2009</xref>). AAV has a 4.7-kb ssDNA genome from which 4.4 kb of the viral DNA can be removed and replaced with a human transgene. Self-complementary (sc) AAV vectors have a 10–100-fold higher transduction efficiency, but their drawback is that their packaging capacity is cut in half to only 2.2 kb, making it difficult to package large genes (McCarty et al. <xref ref-type="bibr" rid="CR131">2001</xref>). When AAV9-<italic>MECP2</italic> under the promoter of chicken β-actin was injected into the brains of neonatal <italic>Mecp2-</italic>null mice, transduction efficiency varied between brain regions from 7 to 42% of cells infected, with the highest infection rate in the hypothalamus and lowest in the striatum (Gadalla et al. <xref ref-type="bibr" rid="CR62">2013</xref>). However, this low efficiency of infection was sufficient to increase lifespan of male mice to 16.6 weeks and improve motor impairments, but it did not have any effect on respiratory symptoms. In contrast, scAAV9-<italic>MECP2</italic> under a truncated <italic>Mecp2</italic> promoter injected into mice systemically had a very low transduction efficiency in the brain of 2–4%. Despite this, mice survived to 15 weeks, indicating that low levels of <italic>MECP2</italic> re-expression in the brain and/or re-expression in non-CNS tissues could modestly improve lifespan. Notably, AAV9 preferentially targeted the liver and spleen, with some cells in these tissues receiving ten copies of the vector and causing liver damage. Therefore, future studies must increase the specificity of AAV9 therapy before moving to the clinic.</p>
<p id="Par44">A subsequent study delivered scAAV9-<italic>MECP2</italic> under a truncated <italic>Mecp2</italic> promoter systemically and found a range of transduction efficiencies in the brain from 10% in the cerebellum to 25% in the cortex and brainstem (Garg et al. <xref ref-type="bibr" rid="CR65">2013</xref>). This produced some behavioral improvements but did not rescue breathing symptoms. A second-generation AAV9 vector with a modified 3′UTR and a panel of miRNA binding sites was developed with the goal of biasing transgene expression away from the liver (Sinnett et al. <xref ref-type="bibr" rid="CR183">2017</xref>). This vector, injected in the cisterna magna, was better tolerated and improved the lifespan of <italic>Mecp2</italic> mutant mice but could not improve behavioral traits without being used at very high doses. However, direct cerebroventricular injection of this vector into neonatal <italic>Mecp2-</italic>null mice resulted in a high brain transduction efficiency, increased survival, and the amelioration of RTT-like phenotypes, highlighting the importance of endogenous regulatory elements in the gene expression cassette (Gadalla et al. <xref ref-type="bibr" rid="CR63">2017</xref>).</p>
<p id="Par45">Finally, a recent study designed a minimal-<italic>MECP2</italic> protein lacking all amino acids except those encoding two functional domains: the methyl-binding domain, and the NCOR-interaction domain (Tillotson et al. <xref ref-type="bibr" rid="CR190">2017</xref>). When neonatal mice were injected intracranially with a scAAV9 vector encoding this minimal protein, they showed improved phenotypes and survival in the absence of toxic effects, indicating that the primary role of <italic>MECP2</italic> is to physically connect the NCOR-containing complex to DNA. This study provides a new avenue to pursue in gene therapy studies as a functional minimal <italic>MECP2</italic> protein creates room for additional regulatory sequences to be packaged into the limited capacity of scAAV9 vectors. Importantly, this would allow for more precise temporal control of <italic>Mecp2</italic> expression. Future studies should aim to introduce additional regulatory elements into the gene therapy vector while also controlling for timing of treatment to best represent therapeutic utility in human patients.</p>
<p id="Par46">An additional obstacle of gene therapy treatment for any disorder involves scaling the dosage for humans. Due to their small size, mice cannot reliably inform effective dosages for clinical applications. Therefore, gene therapy treatment is being tested in other animal models including canines and non-human primates. The brains of non-human primates are similar to humans with regard to neural circuitry, physiology, and behavioral characteristics, making them an ideal model to test gene therapy for neurological diseases (Gopinath et al. <xref ref-type="bibr" rid="CR73">2015</xref>). However, studies in larger models are expensive and require longer experimental periods. Importantly, primate models lacking <italic>MECP2</italic> have been generated which can be utilized to accelerate gene therapy treatment for RTT (Liu et al. <xref ref-type="bibr" rid="CR125">2014</xref>; Chen et al. <xref ref-type="bibr" rid="CR35">2017</xref>). Recently, systemic administration of high-dose AAV9 was found to cause severe liver and neuronal toxicity in three non-human primates indicating that efforts in dosage optimization will be imperative (Hinderer et al. <xref ref-type="bibr" rid="CR88">2018</xref>).</p>
</sec>
</sec>
<sec id="Sec12">
<title>The need for precision medicine for a monogenic disease</title>
<p id="Par47">Rare diseases have limited statistical power in clinical trials making animal models our greatest opportunity at developing, adapting, and enhancing therapeutics to be clinical trial-ready. Importantly, treatments that are rigorously tested and streamlined for efficiency before advancing to human trials achieve higher levels of success than those for which multiple preclinical trials are not conducted (Morgan et al. <xref ref-type="bibr" rid="CR139">2018</xref>). To do this, studies should address age- and method-dependent effects of treatments. For example, in the case of gene therapy, treatment is often more effective in neonatal mice compared to adult mice, or through direct brain injection compared to systemic administration. It is likely that most treatment options will be more effective if delivered to patients early, but as this is not always feasible, preliminary studies should aim to recapitulate treatment methods available in human patients. This would involve testing treatments in <italic>Mecp2</italic> mutant mice after symptom onset. Additionally, identifying and publishing negative effects of potential therapeutics is beneficial as they inform about off-target effects and toxicity. This ultimately provides better criteria to assess the safety of treatments that will lead to the development of more effective therapeutic strategies.</p>
<p id="Par48">While many potential treatments for RTT have been identified in model organisms, many have not shown extreme efficacy in human trials. Clinical trial design for rare diseases is especially important due to the sparsity of patients. In diseases like RTT where there is substantial variability in clinical presentation, patient stratification should be considered to reduce the variability in the sample and maximize the potential to detect efficacy (Modi and Sahin <xref ref-type="bibr" rid="CR137">2018</xref>). Natural history studies assessing genotype–phenotype correlations, symptom progression, and biomarkers of disease may provide tools to identify patients likely to respond to new treatments. For example, there may be critical windows in which specific interventions will have a maximal effect. Additionally, clinical trials should be designed with enough statistical power for the endpoints being tested, with consideration given to placebo effects.</p>
<p id="Par49">Given the drastic variation in phenotype presentation, it is likely that every RTT patient is unique and will not respond to the same treatment. In this respect, precision medicine for RTT is warranted (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). Precision medicine approaches are taken because patients carrying different mutations do not always respond to treatments in the same way. Ideally, RTT patient age, their specific mutation and individual level of XCI skewing should be taken into consideration when developing a personalized treatment regimen. It is likely that some patients will make excellent candidates for gene therapy, mutation read-through, or reactivation of the silent X chromosome, while others may not benefit greatly from any of these treatments.</p>
<p id="Par50">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Precision medicine for RTT. Different RTT patients will likely benefit from different combinations of treatment. When treating patients for RTT, their mutation status and XCI skewing should be taken into consideration. It is likely some patients will not be ideal candidates for gene therapy. Biomarkers, such as serum cholesterol, can be used to determine which patients will benefit from pharmacological intervention, such as statins. Management of other symptoms (seizures, scoliosis, lung infection, etc.) should also be considered. Together, RTT patients should receive individualized treatment to maximize their symptom improvement</p></caption><graphic id="d29e4828" xlink:href="335_2019_9793_Fig4_HTML"></graphic></fig>
</p>
<p id="Par51">As CNS-targeted gene therapy becomes a more realistic therapeutic approach, peripheral deficiency of <italic>MECP2</italic> also needs to be considered. Loss of <italic>MECP2</italic> in non-CNS tissues is associated with cardiac defects (Hara et al. <xref ref-type="bibr" rid="CR86">2015</xref>), decreased bone density (Haas et al. <xref ref-type="bibr" rid="CR81">1997</xref>), urological dysfunction (Ward et al. <xref ref-type="bibr" rid="CR198">2016</xref>), elevated lipid metabolism (Justice et al. <xref ref-type="bibr" rid="CR95">2013</xref>; Segatto et al. <xref ref-type="bibr" rid="CR178">2014</xref>), and increased oxidative stress (Leoncini et al. <xref ref-type="bibr" rid="CR117">2011</xref>). It is likely that when <italic>MECP2</italic> is genetically treated exclusively in the brain, these peripheral symptoms will persist. For this reason, biomarkers of non-CNS perturbations in RTT are needed to ensure adequate treatment. For example, high serum cholesterol or increased oxidative stress can be used as an indicator for statin or triheptanoin treatment, respectively. As more perturbed pathways downstream of <italic>Mecp2</italic> mutation are discovered, it is likely that the list of biomarkers for pharmacological intervention will increase. Importantly, patients should continue to be assessed for seizures, scoliosis, lung infection, and other features of RTT that present differently in each patient. Ultimately, because small increases in <italic>MECP2</italic> can lead to drastic improvements (Carrette et al. <xref ref-type="bibr" rid="CR25">2018</xref>), it is probable that a combination of gene therapy paired with personalized pharmacological treatments will provide the best efficacy to treat most RTT patients. Treating each patient individually is expensive which can reduce profit for drug companies. However, the NIH instituted an orphan drug program to provide incentives for pharma companies to develop treatments for rare diseases such as RTT (Engstrom <xref ref-type="bibr" rid="CR59">1985</xref>).</p>
<p id="Par52">Although it is a rare disorder, RTT has served as a paradigm for the understanding and developing treatments for rare diseases because of the early development of mouse models, intensive mechanistic studies, a NIH-funded natural history study (NCT02738281), and funding by focused patient groups (International Rett Syndrome Foundation and Rett Syndrome Research Trust). Because it is a complex disorder involving many organ systems, it is likely that recovery of RTT patients will involve a combination of treatments. Model organisms will continue to serve as an indispensable tool in accelerating drug discovery and adapting therapeutics, leading to better treatment strategies for many rare disorders.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>We thank all the girls with Rett syndrome and their families who provide the motivation for our group to try to alleviate symptoms. We thank Julie Ruston, Adebola Enikanolaiye, and Rebekah Tillotson for their critical comments on the manuscript.</p>
</ack>
<notes notes-type="funding-information">
<title>Funding</title>
<p>MJJ and NV were supported by grants from the Canadian Institute for Health Research (CIHR) and the Angel Ava Fund while writing this review.</p>
</notes>
<notes notes-type="ethics">
<title>Compliance with ethical standards</title>
<notes notes-type="COI-statement">
<title>Conflict of interest</title>
<p id="Par53">All authors declare that they have no conflict of interest.</p>
</notes>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdala</surname>
<given-names>APL</given-names>
</name>
<name>
<surname>Dutschmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bissonnette</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Paton</surname>
<given-names>JFR</given-names>
</name>
</person-group>
<article-title>Correction of respiratory disorders in a mouse model of Rett syndrome</article-title>
<source/>Proc Natl Acad Sci
          <year>2010</year>
<pub-id pub-id-type="doi">10.1073/pnas.1012104107</pub-id>
<pub-id pub-id-type="pmid">20921395</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdala</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Lioy</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>SK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of sarizotan, a 5-HT1aand D2-like receptor agonist, on respiration in three mouse models of rett syndrome</article-title>
<source/>Am J Respir Cell Mol Biol
          <year>2014</year>
<pub-id pub-id-type="doi">10.1165/rcmb.2013-0372OC</pub-id>
<pub-id pub-id-type="pmid">24351104</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdala</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Toward</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dutschmann</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deficiency of GABAergic synaptic inhibition in the Kölliker-Fuse area underlies respiratory dysrhythmia in a mouse model of Rett syndrome</article-title>
<source/>J Physiol
          <year>2016</year>
<volume>594</volume>
<fpage>223</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1113/JP270966</pub-id>
<pub-id pub-id-type="pmid">26507912</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alpoz</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Ergul</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Oncag</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Bruxism in Rett syndrome: a case report</article-title>
<source/>J Clin Pediatr Dent
          <year>1999</year>
<volume>23</volume>
<fpage>161</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">10204460</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaral</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Pozzo-Miller</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to Induce dendritic spine formation</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<fpage>5179</fpage>
<lpage>5189</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5499-06.2007</pub-id>
<pub-id pub-id-type="pmid">17494704</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amir</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Van den Veyver</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title>
<source/>Nat Genet
          <year>1999</year>
<volume>23</volume>
<fpage>185</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1038/13810</pub-id>
<pub-id pub-id-type="pmid">10508514</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jacoby</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Twenty years of surveillance in Rett syndrome: what does this tell us?</article-title>
<source/>Orphanet J Rare Dis
          <year>2014</year>
<volume>9</volume>
<fpage>87</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-9-87</pub-id>
<pub-id pub-id-type="pmid">24942262</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>The neuropathology of the Rett syndrome</article-title>
<source/>Brain Dev
          <year>1992</year>
<volume>14</volume>
<fpage>S89</fpage>
<lpage>S98</lpage>
<pub-id pub-id-type="pmid">1626639</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artuso</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Papa</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Grillo</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Investigation of modifier genes within copy number variations in Rett syndrome</article-title>
<source/>J Hum Genet
          <year>2011</year>
<volume>56</volume>
<fpage>508</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1038/jhg.2011.50</pub-id>
<pub-id pub-id-type="pmid">21593744</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Batchelor</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>GB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat</article-title>
<source/>Neuropeptides
          <year>2005</year>
<volume>39</volume>
<fpage>81</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.npep.2004.11.001</pub-id>
<pub-id pub-id-type="pmid">15752541</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lioy</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Grunseich</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology</article-title>
<source/>Nat Neurosci
          <year>2009</year>
<volume>12</volume>
<fpage>311</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2275</pub-id>
<pub-id pub-id-type="pmid">19234456</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barton-Davis</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Cordier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shoturma</surname>
<given-names>DI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice</article-title>
<source/>J Clin Invest
          <year>1999</year>
<volume>104</volume>
<fpage>375</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="doi">10.1172/JCI7866</pub-id>
<pub-id pub-id-type="pmid">10449429</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cholesterol levels in Fragile X syndrome</article-title>
<source/>Am J Med Genet A
          <year>2015</year>
<volume>167</volume>
<fpage>379</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36850</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatnagar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic and pharmacological reactivation of the mammalian inactive X chromosome</article-title>
<source/>Proc Natl Acad Sci
          <year>2014</year>
<volume>111</volume>
<fpage>12591</fpage>
<lpage>12598</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1413620111</pub-id>
<pub-id pub-id-type="pmid">25136103</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cholesterol in niemann–pick type C disease</article-title>
<source/>Subcell Biochem
          <year>2010</year>
<volume>51</volume>
<fpage>319</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1007/978-90-481-8622-8_11</pub-id>
<pub-id pub-id-type="pmid">20213549</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bianciardi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fichera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Failla</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MECP2 missense mutations outside the canonical MBD and TRD domains in males with intellectual disability</article-title>
<source/>J Hum Genet
          <year>2016</year>
<volume>61</volume>
<fpage>95</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1038/jhg.2015.118</pub-id>
<pub-id pub-id-type="pmid">26490184</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bienvenu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Carrié</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Roux</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MECP2 mutations account for most cases of typical forms of Rett syndrome</article-title>
<source/>Hum Mol Genet
          <year>2000</year>
<volume>9</volume>
<fpage>1377</fpage>
<lpage>1384</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.9.1377</pub-id>
<pub-id pub-id-type="pmid">10814719</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bittolo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Raminelli</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Deiana</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice</article-title>
<source/>Sci Rep
          <year>2016</year>
<pub-id pub-id-type="doi">10.1038/srep19796</pub-id>
<pub-id pub-id-type="pmid">26806603</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tantra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mollajew</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mild overexpression of Mecp2 in mice causes a higher susceptibility toward seizures</article-title>
<source/>Am J Pathol
          <year>2013</year>
<volume>183</volume>
<fpage>195</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2013.03.019</pub-id>
<pub-id pub-id-type="pmid">23684790</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kottwitz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nuber</surname>
<given-names>UA</given-names>
</name>
</person-group>
<article-title>Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddr602</pub-id>
<pub-id pub-id-type="pmid">22186023</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brendel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Belakhov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model</article-title>
<source/>J Mol Med
          <year>2011</year>
<volume>89</volume>
<fpage>389</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-010-0704-4</pub-id>
<pub-id pub-id-type="pmid">21120444</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Selfridge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lagger</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<fpage>558</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv496</pub-id>
<pub-id pub-id-type="pmid">26647311</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchovecky</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>HM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>1013</fpage>
<lpage>1020</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2714</pub-id>
<pub-id pub-id-type="pmid">23892605</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrette</surname>
<given-names>LLG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C-Y</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders</article-title>
<source/>Proc Natl Acad Sci
          <year>2017</year>
<pub-id pub-id-type="doi">10.1073/pnas.1715124115</pub-id>
<pub-id pub-id-type="pmid">29282321</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrette</surname>
<given-names>LLG</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tsix–Mecp2 female mouse model for Rett syndrome reveals that low-level MECP2 expression extends life and improves neuromotor function</article-title>
<source/>Proc Natl Acad Sci
          <year>2018</year>
<pub-id pub-id-type="doi">10.1073/pnas.1800931115</pub-id>
<pub-id pub-id-type="pmid">30038001</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome</article-title>
<source/>Proc Natl Acad Sci
          <year>2014</year>
<volume>111</volume>
<fpage>9941</fpage>
<lpage>9946</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1311685111</pub-id>
<pub-id pub-id-type="pmid">24958891</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cedar</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>DNA methylation and gene activity</article-title>
<source/>Cell
          <year>1988</year>
<volume>53</volume>
<fpage>3</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(88)90479-5</pub-id>
<pub-id pub-id-type="pmid">3280142</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chahrour</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>The story of Rett syndrome: from clinic to neurobiology</article-title>
<source/>Neuron
          <year>2007</year>
<volume>56</volume>
<fpage>422</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.10.001</pub-id>
<pub-id pub-id-type="pmid">17988628</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chahrour</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>SYY</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title>
<source/>Science
          <year>2008</year>
<volume>320</volume>
<fpage>1224</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="doi">10.1126/science.1153252</pub-id>
<pub-id pub-id-type="pmid">18511691</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandler</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Guschin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Landsberger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wolffe</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA</article-title>
<source/>Biochemistry
          <year>1999</year>
<volume>38</volume>
<fpage>7008</fpage>
<lpage>7018</lpage>
<pub-id pub-id-type="doi">10.1021/bi990224y</pub-id>
<pub-id pub-id-type="pmid">10353812</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Khare</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dani</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression</article-title>
<source/>Neuron
          <year>2006</year>
<volume>49</volume>
<fpage>341</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2005.12.027</pub-id>
<pub-id pub-id-type="pmid">16446138</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chao</surname>
<given-names>H-TT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Samaco</surname>
<given-names>RC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes</article-title>
<source/>Nature
          <year>2010</year>
<volume>468</volume>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1038/nature09582</pub-id>
<pub-id pub-id-type="pmid">21068835</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>RZ</given-names>
</name>
<name>
<surname>Akbarian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice</article-title>
<source/>Nat Genet
          <year>2001</year>
<volume>27</volume>
<fpage>327</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1038/85906</pub-id>
<pub-id pub-id-type="pmid">11242118</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2</article-title>
<source/>Science
          <year>2003</year>
<volume>302</volume>
<fpage>885</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="doi">10.1126/science.1086446</pub-id>
<pub-id pub-id-type="pmid">14593183</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modeling Rett syndrome ising TALEN-Edited MECP2 mutant cynomolgus monkeys</article-title>
<source/>Cell
          <year>2017</year>
<volume>169</volume>
<fpage>945</fpage>
<lpage>955.e10</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.04.035</pub-id>
<pub-id pub-id-type="pmid">28525759</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chin</surname>
<given-names>EWM</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Choline rescues behavioural deficits in a mouse model of Rett syndrome by modulating neuronal plasticity</article-title>
<source/>Mol Neurobiol
          <year>2018</year>
<volume>15</volume>
<fpage>1</fpage>
<lpage>5</lpage>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gabel</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Hemberg</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function</article-title>
<source/>Neuron
          <year>2011</year>
<volume>72</volume>
<fpage>72</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2011.08.022</pub-id>
<pub-id pub-id-type="pmid">21982370</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Levenson</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Vilaythong</surname>
<given-names>AP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mild overexpression of MeCP2 causes a progressive neurological disorder in mice</article-title>
<source/>Hum Mol Genet
          <year>2004</year>
<volume>13</volume>
<fpage>2679</fpage>
<lpage>2689</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddh282</pub-id>
<pub-id pub-id-type="pmid">15351775</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Izaurralde</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species</article-title>
<source/>Curr Opin Cell Biol
          <year>2005</year>
<volume>17</volume>
<fpage>316</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceb.2005.04.005</pub-id>
<pub-id pub-id-type="pmid">15901503</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuddapah</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Pillai</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Shekar</surname>
<given-names>KV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome</article-title>
<source/>J Med Genet
          <year>2014</year>
<volume>51</volume>
<fpage>152</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2013-102113</pub-id>
<pub-id pub-id-type="pmid">24399845</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Ercole</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Calikoglu</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Gutierrez-Ospina</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The role of the insulin-like growth factors in the central nervous system</article-title>
<source/>Mol Neurobiol
          <year>1996</year>
<volume>13</volume>
<fpage>227</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1007/BF02740625</pub-id>
<pub-id pub-id-type="pmid">8989772</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Felice</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic oxidative stress in classic Rett syndrome</article-title>
<source/>Free Radic Biol Med
          <year>2009</year>
<volume>47</volume>
<fpage>440</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.05.016</pub-id>
<pub-id pub-id-type="pmid">19464363</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simone</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of rett syndrome</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<pub-id pub-id-type="doi">10.1038/npp.2011.301</pub-id>
<pub-id pub-id-type="pmid">22157810</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ricceri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fuso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Neonatal exposure to low dose corticosterone persistently modulates hippocampal mineralocorticoid receptor expression and improves locomotor/exploratory behaviour in a mouse model of Rett syndrome</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.05.048</pub-id>
<pub-id pub-id-type="pmid">22940001</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Felice</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Della Ragione</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome</article-title>
<source/>Neurobiol Dis
          <year>2014</year>
<volume>68</volume>
<fpage>66</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.04.006</pub-id>
<pub-id pub-id-type="pmid">24769161</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nativio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for rett syndrome</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<pub-id pub-id-type="doi">10.1038/npp.2014.105</pub-id>
<pub-id pub-id-type="pmid">24809912</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Filippis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Valenti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chiodi</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.03.012</pub-id>
<pub-id pub-id-type="pmid">25890884</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deacon</surname>
<given-names>RMJ</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Snape</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for Fragile X syndrome</article-title>
<source/>NeuroMol Med
          <year>2015</year>
<volume>17</volume>
<fpage>71</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1007/s12017-015-8341-2</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deaton</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>ARW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cell type-specific DNA methylation at intragenic CpG islands in the immune system</article-title>
<source/>Genome Res
          <year>2011</year>
<volume>21</volume>
<fpage>1074</fpage>
<lpage>1086</lpage>
<pub-id pub-id-type="doi">10.1101/gr.118703.110</pub-id>
<pub-id pub-id-type="pmid">21628449</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Matagne</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Banine</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice</article-title>
<source/>Hum Mol Genet
          <year>2007</year>
<volume>16</volume>
<fpage>640</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddm007</pub-id>
<pub-id pub-id-type="pmid">17309881</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deogracias</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yazdani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dekkers</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome</article-title>
<source/>Proc Natl Acad Sci
          <year>2012</year>
<volume>109</volume>
<fpage>14230</fpage>
<lpage>14235</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1206093109</pub-id>
<pub-id pub-id-type="pmid">22891354</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derecki</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Cronk</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wild-type microglia arrest pathology in a mouse model of Rett syndrome</article-title>
<source/>Nature
          <year>2012</year>
<pub-id pub-id-type="doi">10.1038/nature10907</pub-id>
<pub-id pub-id-type="pmid">22425995</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dotti</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Manneschi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malandrini</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in Rett syndrome an ultrastructural and biochemical study</article-title>
<source/>Brain Dev
          <year>1993</year>
<volume>15</volume>
<fpage>103</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/0387-7604(93)90045-A</pub-id>
<pub-id pub-id-type="pmid">8214327</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model</article-title>
<source/>Proc Natl Acad Sci
          <year>2008</year>
<volume>105</volume>
<fpage>2064</fpage>
<lpage>2069</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0711795105</pub-id>
<pub-id pub-id-type="pmid">18272502</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebert</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Gabel</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>ND</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR</article-title>
<source/>Nature
          <year>2013</year>
<volume>499</volume>
<fpage>341</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="doi">10.1038/nature12348</pub-id>
<pub-id pub-id-type="pmid">23770587</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eeg-Olofsson</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Al-Zuhair</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Teebi</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Al-Essa</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Abnormal mitochondria in the Rett syndrome</article-title>
<source/>Brain Dev
          <year>1988</year>
<volume>10</volume>
<fpage>260</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1016/S0387-7604(88)80010-X</pub-id>
<pub-id pub-id-type="pmid">3218707</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elefant</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wigram</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Learning ability in children with Rett syndrome</article-title>
<source/>Brain Dev
          <year>2005</year>
<volume>27</volume>
<fpage>S97</fpage>
<lpage>S101</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2005.03.020</pub-id>
<pub-id pub-id-type="pmid">16182495</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Khoury</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Panayotis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Matagne</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice</article-title>
<source/>PLoS One
          <year>2014</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0092169</pub-id>
<pub-id pub-id-type="pmid">24710502</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engstrom</surname>
<given-names>LO</given-names>
</name>
</person-group>
<article-title>The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development</article-title>
<source/>Prog Clin Biol Res
          <year>1985</year>
<volume>192</volume>
<fpage>25</fpage>
<lpage>30</lpage>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foust</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Nurre</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes</article-title>
<source/>Nat Biotechnol
          <year>2009</year>
<volume>27</volume>
<fpage>59</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.1515</pub-id>
<pub-id pub-id-type="pmid">19098898</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gadalla</surname>
<given-names>KKE</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>MES</given-names>
</name>
<name>
<surname>Cobb</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>MeCP2 and Rett syndrome: reversibility and potential avenues for therapy</article-title>
<source/>Biochem J
          <year>2011</year>
<volume>439</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20110648</pub-id>
<pub-id pub-id-type="pmid">21916843</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gadalla</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Spike</surname>
<given-names>RC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice</article-title>
<source/>Mol Ther
          <year>2013</year>
<volume>21</volume>
<fpage>18</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1038/mt.2012.200</pub-id>
<pub-id pub-id-type="pmid">23011033</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gadalla</surname>
<given-names>KKE</given-names>
</name>
<name>
<surname>Vudhironarit</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hector</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome</article-title>
<source/>Mol Ther-Methods Clin Dev
          <year>2017</year>
<pub-id pub-id-type="doi">10.1016/j.omtm.2017.04.007</pub-id>
<pub-id pub-id-type="pmid">28497075</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandaglia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brivio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Carli</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel Mecp2 Y120D knock-in model displays similar behavioral traits but distinct molecular features compared to the Mecp2-null mouse implying precision medicine for the treatment of Rett syndrome</article-title>
<source/>Mol Neurobiol
          <year>2018</year>
<pub-id pub-id-type="doi">10.1007/s12035-018-1412-2</pub-id>
<pub-id pub-id-type="pmid">30402709</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Lioy</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Cheval</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<fpage>13612</fpage>
<lpage>13620</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1854-13.2013</pub-id>
<pub-id pub-id-type="pmid">23966684</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geisler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fechner</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>MicroRNA-regulated viral vectors for gene therapy</article-title>
<source/>World J Exp Med
          <year>2016</year>
<pub-id pub-id-type="doi">10.5493/wjem.v6.i2.37</pub-id>
<pub-id pub-id-type="pmid">27226955</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goffin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses</article-title>
<source/>Nat Neurosci
          <year>2011</year>
<volume>15</volume>
<fpage>274</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2997</pub-id>
<pub-id pub-id-type="pmid">22119903</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goffin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<collab>Joe</collab>
</person-group>
<article-title>The neural circuit basis of Rett syndrome</article-title>
<source/>Front Biol (Beijing)
          <year>2012</year>
<volume>7</volume>
<fpage>428</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="doi">10.1007/s11515-012-1248-5</pub-id>
<pub-id pub-id-type="pmid">24999353</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gogliotti</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Senter</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Rook</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MGlu5positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome</article-title>
<source/>Hum Mol Genet doi
          <year>2016</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddw074</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gogliotti</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Senter</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>NM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MGlu7potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome</article-title>
<source/>Sci Transl Med
          <year>2017</year>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aai7459</pub-id>
<pub-id pub-id-type="pmid">28814546</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gold</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in the skeletal muscle of a mouse model of Rett syndrome (RTT): implications for the disease phenotype</article-title>
<source/>Mitochondrion
          <year>2014</year>
<volume>15</volume>
<fpage>10</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2014.02.012</pub-id>
<pub-id pub-id-type="pmid">24613463</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonçalves</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adeno-associated virus: from defective virus to effective vector</article-title>
<source/>Virol J
          <year>2005</year>
<volume>2</volume>
<fpage>43</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1186/1743-422X-2-43</pub-id>
<pub-id pub-id-type="pmid">15877812</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gopinath</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nathar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Contemporary animal models for human gene therapy applications</article-title>
<source/>Curr Gene Ther
          <year>2015</year>
<pub-id pub-id-type="doi">10.2174/1566523215666150929110424</pub-id>
<pub-id pub-id-type="pmid">26415576</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Großer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hirt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Janc</surname>
<given-names>OA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome</article-title>
<source/>Neurobiol Dis
          <year>2012</year>
<volume>48</volume>
<fpage>102</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2012.06.007</pub-id>
<pub-id pub-id-type="pmid">22750529</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gregory-Evans</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hodges</surname>
<given-names>MD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic aminoglycoside treatment in rodent models of retinitis pigmentosa</article-title>
<source/>Exp Eye Res
          <year>2008</year>
<volume>87</volume>
<fpage>197</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/j.exer.2008.05.016</pub-id>
<pub-id pub-id-type="pmid">18644591</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hendrich</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome</article-title>
<source/>Nat Genet
          <year>2001</year>
<volume>27</volume>
<fpage>322</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1038/85899</pub-id>
<pub-id pub-id-type="pmid">11242117</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Selfridge</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reversal of neurological defects in a mouse model of Rett syndrome</article-title>
<source/>Science
          <year>2007</year>
<volume>315</volume>
<fpage>1143</fpage>
<lpage>1147</lpage>
<pub-id pub-id-type="doi">10.1126/science.1138389</pub-id>
<pub-id pub-id-type="pmid">17289941</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cheval</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Selfridge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The role of MeCP2 in the brain</article-title>
<source/>Annu Rev Cell Dev Biol
          <year>2011</year>
<volume>27</volume>
<fpage>631</fpage>
<lpage>652</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154121</pub-id>
<pub-id pub-id-type="pmid">21721946</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>The history and challenge of Rett syndrome</article-title>
<source/>J Child Neurol
          <year>1988</year>
<volume>3</volume>
<fpage>S3</fpage>
<lpage>S5</lpage>
<pub-id pub-id-type="doi">10.1177/0883073888003001S02</pub-id>
<pub-id pub-id-type="pmid">3058785</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Nasirian</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative metabolism in Rett syndrome: 2—biochemical and molecular studies</article-title>
<source/>Neuropediatrics
          <year>1995</year>
<volume>26</volume>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-979735</pub-id>
<pub-id pub-id-type="pmid">7566465</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Sartoris</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Hannessy</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Osteopenia in Rett syndrome</article-title>
<source/>J Pediatr
          <year>1997</year>
<volume>131</volume>
<fpage>771</fpage>
<lpage>774</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(97)70113-6</pub-id>
<pub-id pub-id-type="pmid">9403666</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagberg</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Clinical manifestations and stages of Rett syndrome</article-title>
<source/>Ment Retard Dev Disabil Res Rev
          <year>2002</year>
<volume>8</volume>
<fpage>61</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1002/mrdd.10020</pub-id>
<pub-id pub-id-type="pmid">12112728</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Witt-Engerström</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence</article-title>
<source/>Am J Med Genet
          <year>1986</year>
<volume>1</volume>
<fpage>47</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320250506</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Aicardi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases</article-title>
<source/>Ann Neurol
          <year>1983</year>
<volume>14</volume>
<fpage>471</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410140412</pub-id>
<pub-id pub-id-type="pmid">6638958</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Forniceal deep brain stimulation rescues hippocampal memory in Rett syndrome mice</article-title>
<source/>Nature
          <year>2015</year>
<pub-id pub-id-type="doi">10.1038/nature15694</pub-id>
<pub-id pub-id-type="pmid">26605526</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mitsumasu</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disturbance of cardiac gene expression and cardiomyocyte structure predisposes Mecp2-null mice to arrhythmias</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1038/srep11204</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendrich</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tweedie</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The methyl-CpG binding domain and the evolving role of DNA methylation in animals</article-title>
<source/>Trends Genet
          <year>2003</year>
<volume>19</volume>
<fpage>269</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1016/S0168-9525(03)00080-5</pub-id>
<pub-id pub-id-type="pmid">12711219</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinderer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Buza</surname>
<given-names>EL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN</article-title>
<source/>Hum Gene Ther
          <year>2018</year>
<pub-id pub-id-type="doi">10.1089/hum.2018.015</pub-id>
<pub-id pub-id-type="pmid">29378426</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Ishii</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Makita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome</article-title>
<source/>Brain and development
          <year>2001</year>
<publisher-loc>Amsterdam</publisher-loc>
<publisher-name>Elsevier</publisher-name>
</element-citation>
</ref>
<ref id="CR90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2007</year>
<volume>66</volume>
<fpage>117</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1097/nen.0b013e3180302078</pub-id>
<pub-id pub-id-type="pmid">17278996</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tahimic</surname>
<given-names>CGT</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Methyl CpG-binding protein isoform MeCP2-e2 is dispensable for Rett syndrome phenotypes but essential for embryo viability and placenta development</article-title>
<source/>J Biol Chem
          <year>2012</year>
<volume>287</volume>
<fpage>13859</fpage>
<lpage>13867</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.309864</pub-id>
<pub-id pub-id-type="pmid">22375006</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janc</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Hüser</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic radical scavenger treatment of a mouse model of Rett syndrome: merits and limitations of the vitamin E derivative trolox</article-title>
<source/>Front Cell Neurosci
          <year>2016</year>
<pub-id pub-id-type="doi">10.3389/fncel.2016.00266</pub-id>
<pub-id pub-id-type="pmid">27895554</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jentarra</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Olfers</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>SG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation</article-title>
<source/>BMC Neurosci
          <year>2010</year>
<volume>11</volume>
<fpage>19</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2202-11-19</pub-id>
<pub-id pub-id-type="pmid">20163734</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Punzo</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome</article-title>
<source/>J Appl Physiol
          <year>2012</year>
<pub-id pub-id-type="doi">10.1152/japplphysiol.01361.2011</pub-id>
<pub-id pub-id-type="pmid">22961270</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Justice</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Buchovecky</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kyle</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Djukic</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A role for metabolism in Rett syndrome pathogenesis: new clinical findings and potential treatment targets</article-title>
<source/>Rare Dis
          <year>2013</year>
<volume>1</volume>
<fpage>e27265</fpage>
<pub-id pub-id-type="doi">10.4161/rdis.27265</pub-id>
<pub-id pub-id-type="pmid">25003017</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Menniti</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Mather</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>N-methyl-D-aspartate receptors, ketamine, and Rett syndrome: something special on the road to treatments?</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>79</volume>
<fpage>710</fpage>
<lpage>712</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.03.1045</pub-id>
<pub-id pub-id-type="pmid">27079494</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeling</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gunn</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bedwell</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Therapeutics based on stop codon readthrough</article-title>
<source/>Annu Rev Genom Hum Genet
          <year>2014</year>
<volume>15</volume>
<fpage>371</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-genom-091212-153527</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerem</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Konstan</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>De Boeck</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial</article-title>
<source/>Lancet Respir Med
          <year>2014</year>
<volume>2</volume>
<fpage>539</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(14)70100-6</pub-id>
<pub-id pub-id-type="pmid">24836205</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khwaja</surname>
<given-names>OS</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>KV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome</article-title>
<source/>Proc Natl Acad Sci
          <year>2014</year>
<volume>111</volume>
<fpage>4596</fpage>
<lpage>4601</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1311141111</pub-id>
<pub-id pub-id-type="pmid">24623853</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Macklis</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions</article-title>
<source/>Mol Cell Neurosci
          <year>2004</year>
<volume>27</volume>
<fpage>306</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2004.07.006</pub-id>
<pub-id pub-id-type="pmid">15519245</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knudsen</surname>
<given-names>GPS</given-names>
</name>
<name>
<surname>Neilson</surname>
<given-names>TCS</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased skewing of X chromosome inactivation in Rett syndrome patients and their mothers</article-title>
<source/>Eur J Hum Genet
          <year>2006</year>
<volume>14</volume>
<fpage>1189</fpage>
<lpage>1194</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201682</pub-id>
<pub-id pub-id-type="pmid">16823396</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koerner</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>FitzPatrick</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Selfridge</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Toxicity of overexpressed MeCP2 is independent of HDAC3 activity</article-title>
<source/>Genes Dev
          <year>2018</year>
<volume>32</volume>
<fpage>1514</fpage>
<lpage>1524</lpage>
<pub-id pub-id-type="doi">10.1101/gad.320325.118</pub-id>
<pub-id pub-id-type="pmid">30463906</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Pelka</surname>
<given-names>GJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome—Mecp2 gene dosage effects and BDNF expression</article-title>
<source/>Eur J Neurosci
          <year>2008</year>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06305.x</pub-id>
<pub-id pub-id-type="pmid">19087171</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Pelka</surname>
<given-names>GJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Affective dysfunction in a mouse model of Rett syndrome: therapeutic effects of environmental stimulation and physical activity</article-title>
<source/>Dev Neurobiol
          <year>2016</year>
<pub-id pub-id-type="doi">10.1002/dneu.22308</pub-id>
<pub-id pub-id-type="pmid">26019053</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kriaucionis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paterson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome</article-title>
<source/>Mol Cell Biol
          <year>2006</year>
<volume>26</volume>
<fpage>5033</fpage>
<lpage>5042</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01665-05</pub-id>
<pub-id pub-id-type="pmid">16782889</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>CR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTP1B inhibition suggests a therapeutic strategy for Rett syndrome</article-title>
<source/>J Clin Invest
          <year>2015</year>
<volume>125</volume>
<fpage>3163</fpage>
<lpage>3177</lpage>
<pub-id pub-id-type="doi">10.1172/JCI80323</pub-id>
<pub-id pub-id-type="pmid">26214522</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>IT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>13860</fpage>
<lpage>13872</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2159-12.2012</pub-id>
<pub-id pub-id-type="pmid">23035095</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>IT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome</article-title>
<source/>Dis Model Mech
          <year>2014</year>
<volume>7</volume>
<fpage>1047</fpage>
<lpage>1055</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.016030</pub-id>
<pub-id pub-id-type="pmid">25147297</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jaryal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gulati</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cardiovascular autonomic dysfunction in children and adolescents with Rett syndrome</article-title>
<source/>Pediatr Neurol
          <year>2017</year>
<volume>70</volume>
<fpage>61</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.01.010</pub-id>
<pub-id pub-id-type="pmid">28351539</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumaran</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Michaelides</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene therapy for leber congenital amaurosis</article-title>
<source/>Expert Rev Ophthalmol
          <year>2018</year>
<volume>13</volume>
<fpage>11</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1080/17469899.2018.1429916</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuzmiak</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Maquat</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges</article-title>
<source/>Trends Mol Med
          <year>2006</year>
<volume>12</volume>
<fpage>306</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2006.05.005</pub-id>
<pub-id pub-id-type="pmid">16782405</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyle</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>HM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<fpage>3029</fpage>
<lpage>3041</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw156</pub-id>
<pub-id pub-id-type="pmid">27288453</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyle</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Vashi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Justice</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Rett syndrome: a neurological disorder with metabolic components</article-title>
<source/>Open Biol
          <year>2018</year>
<volume>8</volume>
<fpage>170216</fpage>
<pub-id pub-id-type="doi">10.1098/rsob.170216</pub-id>
<pub-id pub-id-type="pmid">29445033</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lalonde</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Strazielle</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Brain regions and genes affecting limb-clasping responses</article-title>
<source/>Brain Res. Rev
          <year>2011</year>
<volume>67</volume>
<fpage>252259</fpage>
<pub-id pub-id-type="doi">10.1016/j.brainresrev.2011.02.005</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laurvick</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>de Klerk</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bower</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rett syndrome in Australia: a review of the epidemiology</article-title>
<source/>J Pediatr
          <year>2006</year>
<volume>148</volume>
<fpage>347</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2005.10.037</pub-id>
<pub-id pub-id-type="pmid">16615965</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawson-Yuen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice</article-title>
<source/>Brain Res
          <year>2007</year>
<volume>1180</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2007.08.039</pub-id>
<pub-id pub-id-type="pmid">17936729</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leoncini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress in Rett syndrome: natural history, genotype, and variants</article-title>
<source/>Redox Rep
          <year>2011</year>
<volume>16</volume>
<fpage>145</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1179/1351000211Y.0000000004</pub-id>
<pub-id pub-id-type="pmid">21888765</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levitt</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Hunnicutt</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Knopp</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A selective 5-HT <sub>1a</sub> receptor agonist improves respiration in a mouse model of Rett syndrome</article-title>
<source/>J Appl Physiol
          <year>2013</year>
<pub-id pub-id-type="doi">10.1152/japplphysiol.00889.2013</pub-id>
<pub-id pub-id-type="pmid">24092697</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Meehan</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Henzel</surname>
<given-names>WJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNA</article-title>
<source/>Cell
          <year>1992</year>
<volume>69</volume>
<fpage>905</fpage>
<lpage>914</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(92)90610-O</pub-id>
<pub-id pub-id-type="pmid">1606614</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bellot-Saez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>ML</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A small-molecule TrkB ligand restores hippocampal synaptic plasticity and object location memory in Rett syndrome mice</article-title>
<source/>Dis Model Mech
          <year>2017</year>
<pub-id pub-id-type="doi">10.1242/dmm.029959</pub-id>
<pub-id pub-id-type="pmid">29125828</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ligsay</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Review of targeted treatments in fragile X syndrome</article-title>
<source/>Intractable Rare Dis Res
          <year>2016</year>
<volume>5</volume>
<fpage>158</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.5582/irdr.2016.01045</pub-id>
<pub-id pub-id-type="pmid">27672538</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linde</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boelz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nissim-Rafinia</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin</article-title>
<source/>J Clin Invest
          <year>2007</year>
<pub-id pub-id-type="doi">10.1172/JCI28523</pub-id>
<pub-id pub-id-type="pmid">17290305</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lioy</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Monaghan</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A role for glia in the progression of Rett’s syndrome</article-title>
<source/>Nature
          <year>2011</year>
<volume>475</volume>
<fpage>497</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="doi">10.1038/nature10214</pub-id>
<pub-id pub-id-type="pmid">21716289</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of MeCP2 (rs2075596, rs2239464) genetic polymorphisms with systemic lupus erythematosus: a meta-analysis</article-title>
<source/>Lupus
          <year>2013</year>
<volume>22</volume>
<fpage>908</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="doi">10.1177/0961203313496340</pub-id>
<pub-id pub-id-type="pmid">23857988</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys</article-title>
<source/>Cell Stem Cell
          <year>2014</year>
<volume>14</volume>
<fpage>323</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2014.01.018</pub-id>
<pub-id pub-id-type="pmid">24529597</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lonetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Angelucci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morando</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 Null mice</article-title>
<source/>Biol Psychiatry
          <year>2010</year>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2009.12.022</pub-id>
<pub-id pub-id-type="pmid">20172507</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyst</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Rett syndrome: a complex disorder with simple roots</article-title>
<source/>Nat Rev Genet
          <year>2015</year>
<volume>16</volume>
<fpage>261</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3897</pub-id>
<pub-id pub-id-type="pmid">25732612</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyst</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ekiert</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>DH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor</article-title>
<source/>Nat Neurosci
          <year>2013</year>
<volume>16</volume>
<fpage>898</fpage>
<lpage>902</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3434</pub-id>
<pub-id pub-id-type="pmid">23770565</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mancini</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dubus</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Jouve</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of desipramine on patients with breathing disorders in RETT syndrome</article-title>
<source/>Ann Clin Transl Neurol
          <year>2018</year>
<pub-id pub-id-type="doi">10.1002/acn3.468</pub-id>
<pub-id pub-id-type="pmid">29468173</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantis</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets</article-title>
<source/>Epilepsy Behav
          <year>2009</year>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2009.02.038</pub-id>
<pub-id pub-id-type="pmid">19249385</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarty</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Monahan</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Samulski</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis</article-title>
<source/>Gene Ther
          <year>2001</year>
<volume>8</volume>
<fpage>1248</fpage>
<lpage>1254</lpage>
<pub-id pub-id-type="doi">10.1038/sj.gt.3301514</pub-id>
<pub-id pub-id-type="pmid">11509958</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCauley</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mike</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome</article-title>
<source/>Sci Transl Med
          <year>2011</year>
<volume>3</volume>
<fpage>113ra125</fpage>
<lpage>113ra125</lpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3002982</pub-id>
<pub-id pub-id-type="pmid">22174313</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonald</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Torricelli</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title>
<source/>Lancet
          <year>2017</year>
<volume>390</volume>
<fpage>1489</fpage>
<lpage>1498</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(17)31611-2</pub-id>
<pub-id pub-id-type="pmid">28728956</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellios</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Woodson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>RI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome</article-title>
<source/>Proc Natl Acad Sci
          <year>2014</year>
<pub-id pub-id-type="doi">10.1073/pnas.1309426111</pub-id>
<pub-id pub-id-type="pmid">24958891</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minkovsky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sahakyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonora</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2′-dC upon inhibition of ribonucleotide reductase</article-title>
<source/>Epigenet Chromatin
          <year>2015</year>
<pub-id pub-id-type="doi">10.1186/s13072-015-0034-4</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mochel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>DeLonlay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Touati</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pyruvate carboxylase deficiency: Clinical and biochemical response to anaplerotic diet therapy</article-title>
<source/>Mol Genet Metab
          <year>2005</year>
<volume>84</volume>
<fpage>305</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2004.09.007</pub-id>
<pub-id pub-id-type="pmid">15781190</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modi</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The way forward for mechanism-based therapeutics in genetically defined neurodevelopmental disorders</article-title>
<source/>Clin Pharmacol Ther
          <year>2018</year>
<volume>104</volume>
<fpage>60306</fpage>
<pub-id pub-id-type="doi">10.1002/cpt.1181</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome</article-title>
<source/>J Neurosci
          <year>2006</year>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2623-05.2006</pub-id>
<pub-id pub-id-type="pmid">16399702</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Lennard</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of a five-dimensional framework on R&amp;D productivity at AstraZeneca</article-title>
<source/>Nat Rev Drug Discov
          <year>2018</year>
<volume>17</volume>
<fpage>167</fpage>
<pub-id pub-id-type="doi">10.1038/nrd.2017.244</pub-id>
<pub-id pub-id-type="pmid">29348681</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Motil</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Caeg</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Barrish</surname>
<given-names>JO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome</article-title>
<source/>J Pediatr Gastroenterol Nutr
          <year>2012</year>
<volume>55</volume>
<fpage>292</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1097/MPG.0b013e31824b6159</pub-id>
<pub-id pub-id-type="pmid">22331013</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mount</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Charman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hastings</surname>
<given-names>RP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Rett syndrome behaviour questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome</article-title>
<source/>J Child Psychol Psychiatry Allied Discip
          <year>2002</year>
<pub-id pub-id-type="doi">10.1111/1469-7610.00236</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Na</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>De Jesús-Cortés</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Martinez-Rivera</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>D-cycloserine improves synaptic transmission in an animal mode of Rett syndrome</article-title>
<source/>PLoS ONE
          <year>2017</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0183026</pub-id>
<pub-id pub-id-type="pmid">29240822</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nag</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Berger-Sweeney</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Postnatal dietary choline supplementation alters behavior in a mouse model of Rett syndrome</article-title>
<source/>Neurobiol Dis
          <year>2007</year>
<pub-id pub-id-type="doi">10.1016/j.nbd.2007.02.003</pub-id>
<pub-id pub-id-type="pmid">17395475</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nag</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Moriuchi</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Peitzman</surname>
<given-names>CGK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Environmental enrichment alters locomotor behaviour and ventricular volume in Mecp21lox mice</article-title>
<source/>Behav Brain Res
          <year>2009</year>
<pub-id pub-id-type="doi">10.1016/j.bbr.2008.07.008</pub-id>
<pub-id pub-id-type="pmid">18957308</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagel-Wolfrum</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Möller</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Penner</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting nonsense mutations in diseases with translational read-through-inducing drugs (TRIDs)</article-title>
<source/>BioDrugs
          <year>2016</year>
<volume>30</volume>
<fpage>49</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1007/s40259-016-0157-6</pub-id>
<pub-id pub-id-type="pmid">26886021</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Maquat</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance</article-title>
<source/>Trends Biochem Sci
          <year>1998</year>
<volume>6</volume>
<fpage>198</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0004(98)01208-0</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Campoy</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin</article-title>
<source/>Cell
          <year>1997</year>
<volume>88</volume>
<fpage>471</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81887-5</pub-id>
<pub-id pub-id-type="pmid">9038338</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nance</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kambhampati</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>ES</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dendrimer-mediated delivery of N-acetyl cysteine to microglia in a mouse model of Rett syndrome</article-title>
<source/>J Neuroinflamm
          <year>2017</year>
<pub-id pub-id-type="doi">10.1186/s12974-017-1004-5</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neul</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Barrish</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome</article-title>
<source/>Neurology
          <year>2008</year>
<volume>70</volume>
<fpage>1313</fpage>
<lpage>1321</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000291011.54508.aa</pub-id>
<pub-id pub-id-type="pmid">18337588</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Gecz</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Nonsense-mediated mRNA decay: inter-individual variability and human disease</article-title>
<source/>Neurosci Biobehav Rev
          <year>2014</year>
<volume>46</volume>
<fpage>175</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.10.016</pub-id>
<pub-id pub-id-type="pmid">24239855</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Leary</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>KV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome</article-title>
<source/>Ann Clin Transl Neurol
          <year>2018</year>
<volume>5</volume>
<fpage>323</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.533</pub-id>
<pub-id pub-id-type="pmid">29560377</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome</article-title>
<source/>J Neurosci
          <year>2007</year>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1869-07.2007</pub-id>
<pub-id pub-id-type="pmid">17913925</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome</article-title>
<source/>Pediatr Neurol
          <year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2016.03.016</pub-id>
<pub-id pub-id-type="pmid">27212420</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orefice</surname>
<given-names>LLL</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>ALL</given-names>
</name>
<name>
<surname>Chirila</surname>
<given-names>AMM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of ASDs</article-title>
<source/>Cell
          <year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.05.033</pub-id>
<pub-id pub-id-type="pmid">28041852</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panighini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Duranti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment</article-title>
<source/>PLoS ONE
          <year>2013</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0064863</pub-id>
<pub-id pub-id-type="pmid">23705018</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Aja</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice</article-title>
<source/>PLoS ONE
          <year>2014</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0109527</pub-id>
<pub-id pub-id-type="pmid">25919298</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paterson</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Belliveau</surname>
<given-names>RA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serotonin transporter abnormality in the dorsal motor nucleus of the vagus in rett syndrome: potential implications for clinical autonomic dysfunction</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2005</year>
<volume>64</volume>
<fpage>1018</fpage>
<lpage>1027</lpage>
<pub-id pub-id-type="doi">10.1097/01.jnen.0000187054.59018.f2</pub-id>
<pub-id pub-id-type="pmid">16254496</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patrizi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>79</volume>
<fpage>755</fpage>
<lpage>764</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.08.018</pub-id>
<pub-id pub-id-type="pmid">26410354</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelka</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Radziewic</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice</article-title>
<source/>Brain
          <year>2006</year>
<pub-id pub-id-type="doi">10.1093/brain/awl022</pub-id>
<pub-id pub-id-type="pmid">16467389</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitcher</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Arvide</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function</article-title>
<source/>Hum Mol Genet
          <year>2013</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddt111</pub-id>
<pub-id pub-id-type="pmid">23462290</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitcher</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Buffington</surname>
<given-names>SA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene</article-title>
<source/>Hum Mol Genet
          <year>2015</year>
<volume>24</volume>
<fpage>2662</fpage>
<lpage>2672</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv030</pub-id>
<pub-id pub-id-type="pmid">25634563</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pizzo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Polyak</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare variants in the genetic background modulate cognitive and developmental phenotypes in individuals carrying disease-associated variants</article-title>
<source/>Genet Med.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41436-018-0266-3</pub-id>
<pub-id pub-id-type="pmid">30190612</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popescu</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sidorova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Eubanks</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro</article-title>
<source/>J Neurosci Res
          <year>2010</year>
<volume>88</volume>
<fpage>2316</fpage>
<lpage>2324</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.22409</pub-id>
<pub-id pub-id-type="pmid">20623622</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puglielli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tanzi</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: the cholesterol connection</article-title>
<source/>Nat Neurosci
          <year>2003</year>
<volume>6</volume>
<fpage>345</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1038/nn0403-345</pub-id>
<pub-id pub-id-type="pmid">12658281</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramirez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Neul</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Breathing challenges in Rett Syndrome: lessons learned from humans and animal models</article-title>
<source/>Respir Physiol Neurobiol
          <year>2013</year>
<volume>189</volume>
<fpage>280</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/j.resp.2013.06.022</pub-id>
<pub-id pub-id-type="pmid">23816600</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renthal</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Hrvatin</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of human mosaic Rett syndrome brain tissue by single-nucleus RNA sequencing</article-title>
<source/>Nat Neurosci
          <year>2018</year>
<volume>21</volume>
<fpage>1670</fpage>
<lpage>1679</lpage>
<pub-id pub-id-type="doi">10.1038/s41593-018-0270-6</pub-id>
<pub-id pub-id-type="pmid">30455458</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rett</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>On a unusual brain atrophy syndrome in hyperammonemia in childhood</article-title>
<source/>Wien Med Wochenschr
          <year>1966</year>
<volume>1946</volume>
<fpage>723</fpage>
<lpage>726</lpage>
</element-citation>
</ref>
<ref id="CR168">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricceri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>De Filippis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fuso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cholinergic hypofunction in MeCP2-308 mice: beneficial neurobehavioural effects of neonatal choline supplementation</article-title>
<source/>Behav Brain Res
          <year>2011</year>
<pub-id pub-id-type="doi">10.1016/j.bbr.2011.03.051</pub-id>
<pub-id pub-id-type="pmid">21457731</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roe</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Sweetman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>DS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride</article-title>
<source/>J Clin Investig
          <year>2002</year>
<volume>110</volume>
<fpage>259</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1172/JCI0215311</pub-id>
<pub-id pub-id-type="pmid">12122118</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roux</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Dura</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moncla</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome</article-title>
<source/>Eur J Neurosci
          <year>2007</year>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05466.x</pub-id>
<pub-id pub-id-type="pmid">18001283</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samaco</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A partial loss of function allele of Methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome</article-title>
<source/>Hum Mol Genet
          <year>2008</year>
<volume>17</volume>
<fpage>1718</fpage>
<lpage>1727</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn062</pub-id>
<pub-id pub-id-type="pmid">18321864</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samaco</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Mandel-Brehm</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McGraw</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome</article-title>
<source/>Nat Genet
          <year>2012</year>
<pub-id pub-id-type="doi">10.1038/ng.1066</pub-id>
<pub-id pub-id-type="pmid">22231481</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Summavielle</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Teixeira-Castro</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome</article-title>
<source/>Neuroscience
          <year>2010</year>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.07.010</pub-id>
<pub-id pub-id-type="pmid">21185356</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaevitz</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Nicolai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Acetyl-L-carnitine improves behavior and dendritic morphology in a mouse model of Rett syndrome</article-title>
<source/>PLoS ONE
          <year>2012</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0051586</pub-id>
<pub-id pub-id-type="pmid">23227269</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaevitz</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Gómez</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Berger-Sweeney</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>MeCP2 R168X male and female mutant mice exhibit Rett-like behavioral deficits</article-title>
<source/>Genes, Brain Behav
          <year>2013</year>
<pub-id pub-id-type="doi">10.1111/gbb.12070</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmid</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ogier</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome</article-title>
<source/>J Neurosci
          <year>2012</year>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0865-11.2012</pub-id>
<pub-id pub-id-type="pmid">23152604</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schon</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Manfredi</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Neuronal degeneration and mitochondrial dysfunction</article-title>
<source/>J Clin Investig
          <year>2003</year>
<volume>111</volume>
<fpage>303312</fpage>
<pub-id pub-id-type="doi">10.1172/JCI200317741</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di Tunno</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cholesterol metabolism is altered in Rett syndrome: a study on plasma and primary cultured fibroblasts derived from patients</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<fpage>e104834</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0104834</pub-id>
<pub-id pub-id-type="pmid">25118178</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahbazian</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Yuva-Paylor</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3</article-title>
<source/>Neuron
          <year>2002</year>
<volume>35</volume>
<fpage>243</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00768-7</pub-id>
<pub-id pub-id-type="pmid">12160743</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahbazian</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Antalffy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation</article-title>
<source/>Hum Mol Genet
          <year>2002</year>
<volume>11</volume>
<fpage>115</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.2.115</pub-id>
<pub-id pub-id-type="pmid">11809720</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Bibat</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hiremath</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bone mass in Rett syndrome: association with clinical parameters and MECP2 mutations</article-title>
<source/>Pediatr Res
          <year>2010</year>
<volume>68</volume>
<fpage>446</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1203/PDR.0b013e3181f2edd2</pub-id>
<pub-id pub-id-type="pmid">20661168</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shulyakova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Eubanks</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in the pathogenesis of Rett syndrome: implications for mitochondria-targeted therapies</article-title>
<source/>Front Cell Neurosci
          <year>2017</year>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00058</pub-id>
<pub-id pub-id-type="pmid">28352216</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinnett</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hector</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Gadalla</surname>
<given-names>KKE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent Toxicity after intracisternal delivery</article-title>
<source/>Mol Ther-Methods Clin Dev
          <year>2017</year>
<volume>5</volume>
<fpage>106</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/j.omtm.2017.04.006</pub-id>
<pub-id pub-id-type="pmid">28497072</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skene</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Illingworth</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state</article-title>
<source/>Mol Cell
          <year>2010</year>
<volume>37</volume>
<fpage>457</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2010.01.030</pub-id>
<pub-id pub-id-type="pmid">20188665</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sripathy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leko</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Adrianse</surname>
<given-names>RL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP/TGF-β superfamily as a regulator of XIST expression</article-title>
<source/>Proc Natl Acad Sci
          <year>2017</year>
<volume>114</volume>
<fpage>1619</fpage>
<lpage>1624</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1621356114</pub-id>
<pub-id pub-id-type="pmid">28143937</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szczesna</surname>
<given-names>K</given-names>
</name>
<name>
<surname>De La Caridad</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Petazzi</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improvement of the rett syndrome phenotype in a mecp2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<pub-id pub-id-type="doi">10.1038/npp.2014.136</pub-id>
<pub-id pub-id-type="pmid">24917201</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function</article-title>
<source/>Proc Natl Acad Sci
          <year>2009</year>
<volume>106</volume>
<fpage>4882</fpage>
<lpage>4887</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0811648106</pub-id>
<pub-id pub-id-type="pmid">19225110</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Coronado</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Negative allosteric modulation of mGluR5 partially corrects pathophysiology in a mouse model of Rett syndrome</article-title>
<source/>J Neurosci
          <year>2016</year>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0672-16.2016</pub-id>
<pub-id pub-id-type="pmid">27881780</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tate</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Skarnes</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse</article-title>
<source/>Nat Genet
          <year>1996</year>
<volume>12</volume>
<fpage>205</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.1038/ng0296-205</pub-id>
<pub-id pub-id-type="pmid">8563762</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tillotson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Selfridge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Koerner</surname>
<given-names>MV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radically truncated MeCP2 rescues Rett syndrome-like neurological defects</article-title>
<source/>Nature
          <year>2017</year>
<volume>550</volume>
<fpage>398</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1038/nature24058</pub-id>
<pub-id pub-id-type="pmid">29019980</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tint</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Irons</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elias</surname>
<given-names>ER</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome</article-title>
<source/>N Engl J Med
          <year>1994</year>
<volume>330</volume>
<fpage>107</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199401133300205</pub-id>
<pub-id pub-id-type="pmid">8259166</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toward</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Abdala</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Knopp</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increasing brain serotonin corrects CO<sub>2</sub> chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice</article-title>
<source/>Exp Physiol
          <year>2013</year>
<pub-id pub-id-type="doi">10.1113/expphysiol.2012.069872</pub-id>
<pub-id pub-id-type="pmid">23180809</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tropea</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Giacometti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>NR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2009</year>
<volume>106</volume>
<fpage>2029</fpage>
<lpage>2034</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0812394106</pub-id>
<pub-id pub-id-type="pmid">19208815</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vacca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Della Ragione</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scalabrì</surname>
<given-names>F</given-names>
</name>
<name>
<surname>D’Esposito</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>X inactivation and reactivation in X-linked diseases</article-title>
<source/>Semin Cell Dev Biol
          <year>2016</year>
<volume>56</volume>
<fpage>78</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2016.03.009</pub-id>
<pub-id pub-id-type="pmid">26994527</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Esch</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bauters</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ignatius</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males</article-title>
<source/>Am J Hum Genet
          <year>2005</year>
<volume>77</volume>
<fpage>442</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1086/444549</pub-id>
<pub-id pub-id-type="pmid">16080119</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viemari</surname>
<given-names>J-C</given-names>
</name>
</person-group>
<article-title>Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>11521</fpage>
<lpage>11530</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4373-05.2005</pub-id>
<pub-id pub-id-type="pmid">16354910</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vigli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Raggi</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome</article-title>
<source/>Neuropharmacology
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.07.029</pub-id>
<pub-id pub-id-type="pmid">30326240</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of MeCP2 causes urological dysfunction and contributes to death by kidney failure in mouse models of rett syndrome</article-title>
<source/>PLoS ONE
          <year>2016</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0165550</pub-id>
<pub-id pub-id-type="pmid">28006024</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wegener</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brendel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of the MeCP2R168X knockin mouse model for Rett syndrome</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<fpage>e115444</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0115444</pub-id>
<pub-id pub-id-type="pmid">25541993</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenk</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>Alterations in dopaminergic function in Rett syndrome</article-title>
<source/>Neuropediatrics
          <year>1995</year>
<volume>26</volume>
<fpage>123</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-979741</pub-id>
<pub-id pub-id-type="pmid">7566450</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of Rett syndrome-like phenotypes in Mecp2-knockout rats</article-title>
<source/>J Neurodev Disord
          <year>2016</year>
<volume>8</volume>
<fpage>23</fpage>
<pub-id pub-id-type="doi">10.1186/s11689-016-9156-7</pub-id>
<pub-id pub-id-type="pmid">27313794</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>YH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of MECP2 gene copy number in boys with autism</article-title>
<source/>J Child Neurol
          <year>2011</year>
<volume>26</volume>
<fpage>570</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.1177/0883073810387138</pub-id>
<pub-id pub-id-type="pmid">21531908</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasui</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Gonzales</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Aflatooni</surname>
<given-names>JO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice with an isoform-ablating Mecp2 exon 1 mutation recapitulate the neurologic deficits of Rett syndrome</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<fpage>2447</fpage>
<lpage>2458</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt640</pub-id>
<pub-id pub-id-type="pmid">24352790</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nagarajan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Klerk</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sleep problems in Rett syndrome</article-title>
<source/>Brain Dev
          <year>2007</year>
<volume>29</volume>
<fpage>609</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2007.04.001</pub-id>
<pub-id pub-id-type="pmid">17531413</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanella</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mebarek</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lajard</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model</article-title>
<source/>Respir Physiol Neurobiol
          <year>2008</year>
<pub-id pub-id-type="doi">10.1016/j.resp.2007.08.009</pub-id>
<pub-id pub-id-type="pmid">18155647</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial cases and male cases with MECP2 mutations</article-title>
<source/>Am J Med Genet B
          <year>2017</year>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32534</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of early-life exposure to THIP on phenotype development in a mouse model of Rett syndrome</article-title>
<source/>J Neurodev Disord
          <year>2016</year>
<pub-id pub-id-type="doi">10.1186/s11689-016-9169-2</pub-id>
<pub-id pub-id-type="pmid">27777634</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>